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Deficiency in B-cell development is the most frequent of primary immunodeficiency disorders 
(PIDD), characterised by complications, making diagnoses and treatment challenging. Patients 
receive intravenous immunoglobulin (IGIV) and micronutrient supplementation to improve 
prognosis, with likely changes in biomarkers. Associations were sought between medico-clinical 
parameters, serum exosomal miRNA and the gut microbiome in patients with PIDD after 
intravenous immunoglobulin (IGIV) and micronutrient supplementation. 
Methodology: 
Ethical approval was granted. Retrospective analysis of data from PIDD (n=48), which included 
phenotypic classification, inflammatory markers, age at presentation and vitamin D levels, on a 
subset (n=27). Intervention studies (n=10) of serum exosomal microRNA expression and the gut 
microbiome were done pre-/post-IGIV and -vitamin (A, E, B, and D) supplementation.  
Results: 
Vitamin D deficiency was apparent in patients, compared to reference ranges. Comparisons 
between patients with PIDD with no complications, as opposed to those with bronchiectasis and/or 
allergy, showed comparable vitamin D levels (p>0.05). Elevated CRP and lower IgG levels were 
apparent in patients with bronchiectasis and allergy complication (p<0.05). White blood cell (WBC) 
counts were higher in patients without complications (p=0.03), perhaps indicating a lower infection 
rate in this group. Bronchiectasis was higher in patients diagnosed at paediatric age (<14 years; 
11 out of 12; 91.7%) compared to adults (9 out of 24; 37.5%) (p=0.002). Smoking was not 
associated with an increased rate of complications, but males appeared more prone to 
bronchiectasis (p=0.003).  
Exosomal miR showed up-regulation in 2 miRNAs (hsa-miR-122-5p and miR-4497) following IGIV 
and vitamin supplementation. No changes in microbiome diversity were seen. 
Conclusion: 
Elevated CRP is a biomarker for B-cell immunodeficiency and bronchiectasis, with miRs, 122-5p 
and 4497, as mediators of both IGIV and vitamin supplementation. The robustness of CRP and 
miRs as biomarkers and their role in PIDD need to be confirmed in larger cohorts. Understanding 
of aetiology of the disease could help design effective therapies and monitoring methods.  
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1.1. Primary Immunodeficiency Diseases (PIDD) 
1.1.1. Definition and background 
Primary immunodeficiency diseases (PIDD) are a group of heterogeneous inherited disorders of 
the immune system1-4, characterised by poor or absent function in one or more components of the 
immune system5-6. Both the acquired form and the inherited subclasses of PIDD that give rise to 
defects in immune system development and function have been described7. PIDD differs from 
secondary immunodeficiency that develops because of haematological malignancies or certain 
immunosuppression medication that is used following transplantation, for systemic autoimmune 
disease, and as part of cancer chemotherapy1,8. The classical understanding of primary 
immunodeficiency disorders is as abnormalities in the development and maturation of cells of the 
immune system. This defect results in increased susceptibility to infection. For example, recurrent 
pyogenic infections occur with defects of humoral immunity and correspond roughly to defects in 
one of the two principal types of immunocompetent cells, B lymphocytes, and opportunistic 
infections with defects in cell-mediated immunity that correspond to T lymphocytes defects, and, 
therefore, to cellular immunity9. However, the clinical manifestations of PIDDs are highly variable4, 
and patients with PIDD may present with increased susceptibility to infection, immune 
dysregulation (autoimmune disease and aberrant inflammatory responses), and malignancy1.  
Currently, the term primary immunodeficiency is considered a limitation to the wide spectrum of 
the disease and depicts only the susceptibility to infection as the main manifestation. Advances in 
the understanding of the broader meaning of PIDD have led to the inclusion of immune 
dysregulation diseases, auto-inflammatory disorders, and interferonopathies. The use of the 
phrase ‘inborn errors of immunity’ was utilised as a descriptive term in the 2017 updated 
classification of the disease entities by the International Union of Immunological Societies (IUIS)2. 
1.1.2. Description and classification  
PIDDs are classified into nine distinct categories based on a combination of mechanistic and 
clinical descriptive characteristics by IUIS 2017 (Table 1). These categories are further divided 
into disease sub-categories according to common phenotypes. However, despite such phenotypic 
classification, it should not be assumed that the presentation of those immunodeficiency disorders 
is homogeneous. A few points of importance in the 2017 updated classification are that the mode 
of inheritance is not one of the classification criteria, and any defective gene can be the cause in 
more than one phenotype. To date, nine genes have been reported: CFB, C3, CARD11, STAT1, 
22 
 







IUIS Classification and Division into Disease Groups 
1. Combined T- and B-cell immunodeficiency 
2. Combined immunodeficiencies with associated or syndromic features 
3. Predominantly antibody deficiencies 
4. Diseases of immune dysregulation 
5. Congenital defects in phagocyte number and/or function 
6. Defects in natural immunity (innate immunity) 
7. Auto-inflammatory disorders 
8. Complement deficiencies 
9. Phenocopies of inborn errors of immunity.  
 
Table 1: The 2017 IUIS phenotypic classification for primary immunodeficiencies.  
Nine subcategories of Primary Immunodeficiency were established by the Inborn Errors of 
Immunity Committee (IEI), which consists of experts in primary immunodeficiencies and contribute 
to the biennial IEI classification reports under the umbrella of the International Union of 






1.1.3. Epidemiology: Prevalence, Age, Sex, and Ethnicity  
PIDD is not a common disorder, and few countries have established a registry to improve the 
reliability and quality of the epidemiological data. However, many do not have available 
information, and even those with registries are facing under-reporting, a lack of awareness, and 
under-diagnosis; factors which, in combination, lead to the underestimation of prevalence10. Since 
February 2017, 354 PIDD have been established by the Inborn Errors of Immunity (IEI) committee. 
These disorders were categorised with 344 different gene defects and a wide spectrum of 
phenotypes2. 
National, transnational and international registries are identifying missing data about these 
diseases (Figure 1). The currently available international registries aim to predict the prevalence, 
rate and different types of these rare disorders11-12. The increase in physicians’ awareness and 
recognition allowed its reported prevalence to increase from 38.9 to 50.5 per 100,000 among the 
privately insured, and from 29.1 to 41.1 per 100,000 publicly insured persons, from administrative 
healthcare databases between 2001 and 2007 in the USA. Moreover, it was found that B-cell 
defects predominated and that the prevalence was more than double in Caucasian Americans 
(Whites), compared with African Americans or Hispanics11-13. This figure is comparable with the 
prevalence of 1 in 2000 to 1 in 1200 live births estimated in the USA2,14. While most forms of PIDD 
are rare, with incidences of around 1 in 500,000 of the population, some specific PIDD are 
relatively common. One of these immunodeficiencies is IgA deficiency, which accounts for 1 in 
500 in Caucasian populations, yet only accounts for 1 in 18,000 in East Asians12. However, much 
is dependent on the diagnostic skills and medical resources available in different countries15.  
The prevalence of PIDD from the published literature and different countries’ registries has 
received particular attention internationally10-28. The ESID, for example, went online in 2004 and is 
one of the most important and popular resources for researchers and physicians interested in 
immunodeficiency. As of January 2019, predominantly antibody disorders account for 10,612 of 
cases (50.4%), other well defined PIDs account for 2967 (14.1%), and combined 
immunodeficiencies account for 2041 (9.7%)16,19-21. European countries including Italy, France, 
and Spain initially had their own registries, but subsequently adopted the ESID platform10-13,19-21. 
The National United Kingdom Primary Immunodeficiency (UKPID) Registry adopted the ESID 
platform in 2005. The second published report from the UKPID indicated a doubling of PIDD (from 
2229 to 4758 patients) with a minimum PID prevalence of 5.90/100,000 and an average incidence 
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of 7.6 cases per 100 000 UK live births between 1980 and 2000. The report also showed that 
females accounted for 2399, those aged 16 years or less for 807 (17%), there was a molecular 
diagnosis in 1035 patients (21.8%), consanguinity in 118 of 4097 patients (2.9%) and familial 
cases accounted for 3971 (24.4%). The antibody disorders dominate, with 2821 (59.7%), of which 
CVID is the most frequently reported PID (1404; 29.7%)22. The US Immunodeficiency Network 
(USIDNET) Registry began in 1992 and reported 2622 predominantly antibody disorders among 
5204 participants24. The Latin American Group for PIDD registry is one of the oldest registries 
(established in 1993) to have adopted the ESID platform. PAD represented 53.2% of the 3321 
registered PIDD25. The Australasian Society of Clinical Immunology and Allergy Registry (ASCIA 
PID) Register in Australia and New Zealand was launched in 2003. They reported 1209 cases 
(70% with PAD), with an estimate of the true prevalence of 13.2–14.5/100,00026. The Iranian 
Primary Immunodeficiencies Registry is one of the geographically closest registries to Qatar. Over 
30 years of experience in PIDD, they reported 3056 (1204 females) from 31 medical centres. The 
predominantly antibody deficiency was the most common, with 903 cases (29.5%). The genetic 
defect was identified in 1014 patients (33.1%); 79.3% were autosomal recessive and combined 
immunodeficiencies, with associated or syndromic features accounting for 529. The cumulative 
incidence of PID in Iran during the past ten years was estimated to be around 81 cases per 
1,000,000 inhabitants27. In the Middle Eastern region consanguinity is high, around 20-56% as 
opposed to 1-9% globally, and contributes significantly to genetic disorders such as PIDD. 
Countries in this region, including: Morocco, Tunisia, Israel, Kuwait, Iran Egypt, Turkey, Saudi 
Arabia, Qatar, and Oman, have reported PIDD from their national registry, survey or referral 
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Figure 1c: PIDD distribution in the MENA region. 
Figure 1.0: Relative Frequency and Prevalence of PIDDs (Global & MENA). 
1a: Relative frequencies of primary immunodeficiency diseases as described by Rezaei et al. The 
pie chart showed that >50% represent cases with predominantly antibody deficiencies across the 
world.  
1b: Distribution of different types of primary immunodeficiency diseases in the world. The 
predominantly antibody deficiency prevalence varies across the globe, and we can see that the 
disease prevalence is less than 50% in some countries.  
1c: The Middle East and North Africa (MENA) countries have higher consanguinity than other 
countries in the globe (reaching up to 56%). Hence, the rate of PIDD is expected to be higher. The 
chart showed the frequencies in the MENA region in comparison to the European prevalence. 
While antibody deficiency is predominant, some Arab countries showed a lower prevalence with 
a higher prevalence of combined immunodeficiency, namely KSA, Egypt, and Tunisia. (Note: 
adapted from Rezaei et al. 2017 12 and Al-Mousa et al. 2017 28). 
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1.1.4. Clinical evaluation and management of PIDD  
Whilst evaluating immunodeficiency, it is important, where possible, to document the origin and 
type of infections, the causative organisms, and the treatment course and response. Such 
evaluation is necessary to detect other non-infectious conditions, such as allergy, or to distinguish 
viral from bacterial infections. Anatomical defects, allergy, and metabolic disorders should be 
considered during different PIDD evaluation and attention paid to some diagnostic hints, such as, 
the presence of food and inhaled allergic diseases. In general, from a clinical perspective, taking 
proper history and following up the clinical presentation aids in the diagnosis and management. 
Using simple screening tests such as complete blood count followed by advanced tests is the 
usual approcah1-2. Serious morbidity and early mortality may be prevented by accurate and early 
diagnosis and a stepwise approach that includes a clinical and immunological evaluation with the 
help of the international diagnostic protocols designed by the European Society for 
Immunodeficiencies (ESID)29, followed by flow cytometric immunophenotyping and functional 
studies. This approach guides the selection of candidate genes for molecular diagnostics.  
The genetic defect has not yet been identified in all PIDD patients. Moreover, the diversity of the 
clinical presentation of PIDD with genetic defects in known candidate genes are increasing, which 
necessitates more extensive diagnostic testing in specific cases30-31. Two common causes are to 
be considered when evaluating immune-related conditions. The first is HIV infection. It is one of 
the ten leading causes of death in the USA among the age groups from 15-6532. HIV testing is 
mandatory when evaluating cases of PIDD33. The second is nutritional status, specifically, 
malnutrition. Nutrition is one of many factors that may affect the immune system, and malnutrition 
does not just mean energy and protein deficiency. Macronutrients (fat, carbohydrate, protein), as 
well as micronutrients deficiency (vitamins, minerals, water), are harmful to immune functions. 
Balanced nutrition helps in the body’s protection against infection and supports immune function34-
35. Immuno-nutrition is a term used to describe special diets believed to augment the immune 
system. In meta-analyses, the benefit of immune-nutrition was pronounced in surgically ill 
patients36-37.  
Some attention has been focused on the use of multiple micronutrients as a means of improving 
the immune system, including essential amino acids, the essential fatty acid linoleic acid, vitamin 
A, folic acid, vitamin B6, vitamin B12, vitamin C, vitamin E, Zn, Cu, Fe, and Se38.  
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Multiple studies have also been conducted to evaluate the effect of diet at a cellular level. One 
study, in which the effect of exercise and two unbalanced diets was evaluated in mouse models, 
revealed that changes in leptin and adiponectin levels were associated with the increases in total 
lymphocytes, CD4+ cells, and CD8+ cells. This was also associated with a reduction in B-cells. 
These diets were found to play a role in the induction of glycaemia and oxidative stress that modify 
the proliferation of total lymphocytes and the percentage of B-cells, through alterations in proteins 
by carbonylation. This phenomenon was not altered by moderate exercise39. In another study, a 
potential health benefit was suggested by consuming fruit and vegetable juice powder 
concentrate capsules that leads to the suppression of peripheral blood lymphocyte (PBL) DNA 
damage40. The effects of other micronutrients (vitamins A and D) on the immune system were also 
studied34. 
1.2. Predominant antibody deficiency (common variable immunodeficiency, CVID, 
and specific antibody deficiency, SAD)  
Predominant or primary antibody deficiencies (PAD) is the second category under 2017 IUIS 
classification2. It requires lifelong replacement therapy with immunoglobulin (Ig)G to reduce the 
incidence and severity of infections41. Diseases under this category include X-linked 
agammaglobulinaemia, X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich 
syndrome, selective IgG class deficiency with specific antibodies deficiency, and common variable 
immunodeficiency (CVID), among others2. PAD causes recurrent bacterial infection affecting 
multiple systems, including the gastrointestinal and respiratory tracts. Affected individuals have 
changes in B-cell function, reduced levels of naïve T cells and Treg cells, an increased risk of 
malignancy, chronic immune activation, altered levels of cytokine production, and autoimmunity7. 
PAD might depend on a variety of defects that interfere with B-cell development, maturation, 
and/or function. PAD form the largest category, followed by combined B- and T-cell deficiencies2,42. 
The subclass SIgAD is the most common of all PIDD, yet most patients with SIgAD are 
asymptomatic. 
In contrast, CVID is the commonest clinically relevant primary immunodeficiency15. The different 
B-cell deficiency diseases are directly related to the stage at which B-cell development and arrest 






Figure 2: The effect of the monogenic defect on the B-cell development in PIDDs.  
The following primary antibody deficiency diseases (X-linked agammaglobulinaemia (XLA), 
selective IgA deficiency (SIgAD), Common Variable Immunodeficiency (CVID), and Hyper IgM 
syndrome (HIGM) have defects or arrest in B-cell developmental different stages and can be 
explained using examples of monogenic defects. The genetic defects at different locations lead to 
different antibody deficiency diseases. In X-Linked agammaglobulinaemia (BTK gene), the B-cell 
arrest occurs at the preB-cell, i.e. early in B-cell development); a process happens in the bone 
marrow (antigen-independent pathway) and results in the absence of B-cells, leading to an 
absence of Igs. In contrast, in the periphery (via the antigen-dependent pathway), the CVID, 
SIgAD, and HIGM develop due to B-cells being unable to differentiate into various different Ig 
isotype-producing cells, thereby resulting in variable degrees of Ig deficiency. In hyper-IgM 
syndrome (HIGM), defects in switching from IgM isotype production into the production of other 
isotypes resulted in high levels of IgM and low levels of other Igs (Note: adapted from Driessen et 




1.2.1. Common Variable Immunodeficiency 
Common variable immunodeficiency (CVID; OMIM*240500), represents a heterogeneous group 
of syndromes characterised by low levels of immunoglobulins and impaired antibody response to 
both polysaccharide and protein antigens. Moreover, patients have increased susceptibility to 
autoimmunity and malignancy15,47. The involvement of different organs is observed in patients with 
CVID (Figure 3). Fewer than 10% of CVID have a definitive molecular genetic diagnosis; similarly, 
fewer than 10% have a positive family history15,47. 
According to data from the ESID registry, 30% of the patients had CVID. Both sexes are affected 
equally. The prevalence is 1 in 50,000 to 1 in 200,000, with a reported incidence of 1 in 75,000 
live births. The disease is sporadic in distribution, with up-to 25% having a family history, typically 
with autosomal dominant inheritance. The disease can present in mid-childhood to mid-adulthood; 
however, it can be variable. These data give an overview of the age at presentation of CVID and 
shows that it has a bimodal distribution14. The largest series of CVID by Cunningham-Rundles et 
al included 248 patients aged 3–79 years with an average delay of diagnosis from the onset of 
symptoms of around 5-6 years in male and female respectively47. Regional differences are often 
an issue in genetic disorders, and depend on many factors. Asians and Afro-Americans have lower 
rate of CVID. The disease can occur at any age and it seems that both male and female have 
similar incidence of development of the disease11. 
Interestingly, in Finland, CVID was found to be more prevalent than expected48, likely due to the 
genetic isolation and potential founder effects in the Finnish population. Also, this can be attributed 
to the progressively improved diagnosis and awareness in the primary health care sector. 
1.2.2. Selective IgA, IgG2 subclass, and specific anti-polysaccharide antibody deficiency  
In IgA and IgG subclass deficiency, terminal differentiation of B-cells fails. SIgAD is the most 
common immunodeficiency, with 1 in 500 Caucasians having the defect. However, it is not 
common in other ethnic groups, such as in Asians. People with SIgAD have tendency for immune-
complex diseases (Type III hypersensitivity) and allergies. Also, recurrent infection with 
encapsulated organisms is frequent in up to 20% of IgA-deficient individuals due to concomitant 
lack IgG2 and IgG4 immunoglobulin subclasses. A deficiency of IgG2 alone is a predisposing 
factor to recurrent infections because most antibodies to the capsular polysaccharides of pyogenic 
bacteria are of the IgG2 subclass. These class and subclass deficiencies result from a failure in 
the terminal differentiation of B-cells. The post-pneumococcal polysaccharide vaccination 
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response is one of the tests used in the clinical immunology practice to evaluate patients with 






Figure 3: CVID can affect multiple organs and systems in the human body.  
Immune disturbances in common variable immunodeficiency resulted in recurrent infections, 
autoimmune, bronchiectasis, and lymphoproliferative complications (Note: adapted from Rezaei 






Serotypes  Conjugate Vaccine 
Antibodies level  
by ELISA (mg/L) 
Antibodies 
level by  
multiplex bead 
assay (mg/L) 
  PCV-7 PCV-10 PCV-13 3-15 yrs. 19-30 yrs. 3-30 yrs. 3-30 yrs. 
1   X X       0.53 
3     X 0.99 0.58 0.67 0.64 
4 X X X 0.73 0.37 0.45 0.49 
6B X X X       0.8 
7F   X X       1.45 
8             1.02 
9N       0.78 0.23 0.46 0.63 
9V X X X       0.69 
12F             0.46 
14 X X X       0.57 
18C X X X 0.55 0.31 0.31 0.34 
19A     X       0.96 
19F X X X 1.66 0.91 1.04 0.74 
23F X X X       0.25 
 
Table 2: PIDD assessment by evaluating post-vaccination response (measuring 
pneumococcal polysaccharide serotypes before and after the vaccine).  
An important part of the evaluation of humoral Immunodeficiency is done through measuring post 
pneumococcal vaccine response (by measuring serum specific serotypes before and 2-6 weeks 
following vaccination). The common pneumococcal serotypes used in clinical practice to evaluate 
cases with PAD are listed above. The cut-off value for each serotype, based on different laboratory 








1.3 Potential mediators of PIDD  
Multiple factors, including Immunoglobulin IGIV administration, microbiome composition, and the 
deficiency of various micronutrients, have been assessed as potential mediators of CVID49-57. 
While micronutrients were observed to induce particular disease phenotypes49-51, the different 
cytokines (IL-10, IL21, and IL-4) have also received attention and been evaluated in different 
clinical phenotypes of CVID patients52. Microbiome and microbial dysbiosis play meticulous roles 
in immune homeostasis and during inflammatory response. However, there are currently very few 
studies that suggest unifying or multiple mechanisms for the observed clinical outcome53-57. The 
various factors that are set out below merit further investigation. 
1.3.1. Immunoglobulin replacement therapy has an immunomodulatory effect on PIDD 
IGIV has proven to be an effective treatment for many diseases, including PIDD. It works as anti-
inflammatory and immunomodulator for multiple autoimmune diseases and is given in high doses 
for this purpose. For PIDD, IGIV is administered at lower concentrations as a replacement therapy. 
Although the full immunomodulatory mechanism(s) are not fully understood, multiple mechanisms 






Figure 4: components of IGIV that exerts function.  
Four components in the IGIV preparation summarized by Sewell et al.: (1) the variable regions 
F(ab′)2, (2) Fc on Fc receptors (FcR), (3) complement binding within the Fc fragment, and (4) other 
immunomodulatory substances other than antibody in the IGIV preparations. (TCR, T-cell 
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1.3.2. Micronutrients play a recognized role 
The nutritional status of an individual has been shown to have a significant effect on the immune 
system, both at the macro- and micronutrient levels. There has been long-standing interest in the 
effect of micronutrients, as they can be used in low doses to affect a change. The vitamins have 
been investigated extensively in the immune milieu. Vitamins play an important role in growth and 
development, with important neurologic and digestion functions, by supporting the immune 
system. Moreover, they also maintain normal cellular function in general. Vitamin deficiency 
depresses the production and causes dysfunction of immune cells. It is well documented that 
vitamins are considered important in metabolism and are effective in provoking resistance and 
inducing immunity. Vitamin A, vitamin C, pyridoxine, pantothenic acid, and thiamine have a role in 
fighting infections, with roles in immunity also reported for B and D vitamins61. 
Vitamin B6  
Vitamin B6 deficiency causes skin, nerve, and coronary artery disease. The deficiency of vitamin 
B6 is mainly associated with malnutrition, malabsorption, and immunodeficiency. In patients with 
CVID, plasma vitamin B6 levels were found to be reduced. In peripheral blood, the reduced vitamin 
B6 was not found to be associated with CD4, CD8, CD16, and CD20+. Three months of treatment 
with 50mg of vitamin B6 improved vitamin B6 and CD4+ lymphocytes. The concentration of IgG, 
IgM, and IgA was not found to have any association with vitamin B6 treatment. This study reported 
that vitamin B6 deficiency is common in individuals with CVID. However, its supplementation did 
not improve humoral immunodeficiency49,62-63. 
Vitamin A  
Vitamin A deficiency is a predisposing factor for infections of the GI and respiratory tracts64-65. In 
patients with immunodeficiency, deficiency of this vitamin has an immunomodulating effect. CVID 
individuals were found to have low vitamin A levels compared to healthy individuals. CVID 
individuals with malnutrition, bacterial infection, and splenomegaly individuals have lower vitamin 
A levels 66-67. However, whether this deficiency can modulate the onset of disease or modulate its 
progression and/or associated pathologies is unclear. The administration of vitamin A (6500 IU 
per day), for six months, increased vitamin A levels in CVID individuals. Furthermore, it was 
associated with an increase in the concentration of the anti-inflammatory cytokine, IL-10, and a 
decrease in the pro-inflammatory cytokine, TNF-α. The supplementation of vitamin A enhanced 
IgA levels. However, no significant changes in IgM levels were observed. This study supported 
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the contention that vitamin A supplementation enhances anti-inflammatory cytokines and 
immunoglobulin levels while suppressing pro-inflammatory cytokines, in CVID individuals66. 
Vitamin B12  
B12 deficiency is considered a cause of impaired immunoglobulin production68, and both vitamin 
B12 and folic acid imbalance modify NK cytotoxicity, B lymphocytes and lymphoproliferation in 
mouse models69. 
Vitamin D  
Paulino et al. examined vitamin D levels and found a high percentage of 25-hydroxyvitamin D 
deficiency in the Ataxia-telangiectasia group (6/14; 42.8%) and CVID group (3/17; 17.6%)70. 
Vitamin E  
In two case series, it was speculated that patients with CVID and enteropathy might be relatively 
susceptible to developing symptomatic vitamin E deficiency. This report suggested that vitamin E 
deficiency may be a potential factor of unexplained neurological disease with retinitis pigmentosa 
in 5 out of 14 patients in PAD51. In addition to these case series, it has been reported that lower 
serum level of vitamins A and E are present in patients with PID, but not for vitamin D. Also, in 
PIDD, the decreased serum vitamin A levels were positively correlated with reduced IgG levels. 
However, there was no significant association between their immunological specifications and 
vitamin E levels71. 
Zinc  
Acrodermatitis enteropathica and SCID-like syndrome are features associated with zinc 
deficiency64. Comparison of different levels of vitamin A and zinc found that CVID patients had 
lower levels of retinol and zinc than controls. This deficiency may contribute to their disease 
severity leading to a state of chronic inflammation. Therefore, it may be recommended that 
micronutrient status is always checked in patients with primary immunodeficiency64.  
 
1.3.3. Microbiome as an immunomodulator  
Few studies have shown that the microbiota may activate and help to condition host immunity. 
The relationship between altered gut microbiota and the PIDD, especially CVIDs, was more explicit 
and linked to autoimmunity conditions in a few studies54,72. The expression of different B-cell 
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phenotypes was studied together with gut microbiota in mice models. Data showed that the gut 
microbiota boosts regulatory B cells differentiation in both the spleen, and the mesenteric lymph 





Figure 5a: Control of the microbiome in health (left panel) and in CVID (right panel). 
The mechanisms leading to immune dysregulation in a normal control of the microbiome (left 
panel) and the reduced control of the microbiome in CVID (left) (Abbreviations: CVID, Common 





Figure 5b: Factors leading to immune dysregulation in CVID.  
The reduced control of the microbiome in CVID is one of the factors that may lead to immune 
dysregulation.  
Figure 5.0: Microbiome in health and disease (CVID) and mechanisms leading to immune 
dysregulation. 
Susceptibility to CVID in combination with other factors, may lead to microbial dysbiosis and can 
lead to a vicious cycle leading to inflammation and a state of immune dysregulation (Note: adapted 





1.3.4. miRNA may potentially be a modulator and a target for preventative and therapeutic 
options  
miRNAs are small molecules (21-25 oligonucleotides) that regulate gene expression, at the stage 
following transcription, and may lead to mRNA degradation and the inhibition of translation74-75. 
They are secreted in exosomes, other microvesicles, and lipoproteins from different cells types76-
77 into the circulation and may also act as biomarkers of diseases78. The use of miRNAs is under 
investigation as part of an attempt to produce personalised therapies like miRNA antagonists79 
and transferring specific molecular functions to cells that receive exosomes80 (Table 3). There 
have been a few reports in animal models of miRNAs playing a role in the immune system81. 
1.3.5. The development of “Triad Interaction Theory” (miRNA, microbiome, and 
micronutrients) for PIDD patients  
There have been no previous studies of dietary change, causing disease modulation in patients 
with PIDD. Also, no studies have been reported evaluating the relationship between miRNA and 
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Table 3: MicroRNA therapeutic development. 
Several miRNAs are currently at the preclinical and clinical stages and may soon be available for 






Primary Immunodeficiency, particularly predominantly antibody deficiency, is a group of disorders 
that predispose affected individuals to body organs’ destruction and complications (bronchiectasis, 
autoimmunity, malignancy, and allergy) and result in lifelong disabilities and a decreased quality 
of life. The relationship and association between immune cells, miRNA, microbiome, and 
micronutrients are not well established in the literature. Studying this relationship was the aim of 
this project. Identifying novel biomarkers and meaningful stratification may lead to a better 
understanding of the aetiology of the disease, thereby helping to personalise effective therapy and 
improve monitoring methods. The detailed results (miRNA and microbiome) from this study may 







Figure 6: The interaction between immune cells, microbiome and dietary modulators in 























1.5. Aims and objectives of the project  
1.5.1. Research hypothesis 
Current literature shows that there is a relationship between diet, miRNA signature in immune 
cells, and the microbiome. Patients with PIDD (either causally, or as a consequence) appear to 
have different microbiome profiles associated with the disease. Equally, changes in miRNA may 
be related to these changes, and the symptoms and prognosis of patients with PIDD may be 
influenced through and by dietary modification. Therefore, the study proposed to investigate the 
following aims and objectives.  
1.5.2. Aims and Objectives 
1.5.2.1. The main objectives were to investigate the following 
• The interaction between immune cell phenotype and the gut microbiome in patients 
with B-cell diseases prior to any intervention 
• The effect of, either alone or combined, the commencement of intravenous 
immunoglobulin (IGIV) (short- and long-term effects) and supplementation with 
micronutrients (multivitamins) on:  
➢ Patients’ symptoms, by measuring clinical, physiological and biochemical markers 
and by conducting symptoms and dietary questionnaires before, during intake and 
after stopping MVT to evaluate other dietary effects and the improvement of patient 
symptoms and safety. 
➢ Immunological cell signatures, exosomal micro RNA, and gut microbiomes. 
 
1.5.2.2. Secondary objectives were to investigate 
• Correlations between circulatory cytokines, vitamins levels, and the microbiome in 
patients with PIDDs with the clinical diagnostic disease and different phenotypes.  
• Regrouping (re-stratifying) B-cell PIDDs based on phenotypes, diagnosis and 
lymphocytes’ signature. 
• Relationships between the triad (micronutrients, microbiome, and 






















2.1.1. Study plan and design 







Figure 7: Summary of the study design.  
The study is composed of three parts. The first stage is a chart review of patients with PIDD who 
were followed in immunology clinics. The second stage is conducting a questionnaire-based cross-
sectional study, and the third stage is selecting ten patients for the intervention. 




2.1.2. Ethical approval and funding application 
The process of obtaining ethical approval for the research started directly following the receipt of 
the offer for the MRes by the University of Bristol in September 2017. It is consistent with ensuring 
that the human rights of research participants and researchers were both protected. The 
guidelines and policies provided by the Department of Medicine, Pulmonary and Allergy Division 
Medical Research Centre (MRC) in Hamad Medical Corporation (HMC) were followed during the 
application process, and official documentation was produced. These guidelines are in alignment 
with the University of Bristol Research guides. A full proposal (13 pages) was submitted, with two 
consent forms (Informed consent and Assent consent- English and Arabic forms), data collection 
sheet and the two questionnaires that were to be used in the study. This process took three months 
of preparation and submission. The papers passed the MRC scientific review and were approved 
in November 2017. 
 
Following the approval of the MRC, papers were transferred to the Institutional Review 
Board (IRB) (Research Ethics Committee) of the HMC to deal with the application in accordance 
with the agreed local policy, procedures and regulations governing human subject studies. Six 
weeks were required for final approval. The application received final approval in December 2018. 
The study was awarded a grant of 19,592.76 GBP in January 2018. An amendment to exceptional 
upgrade of the budget to reach around 30,300 GBP was made and received approval in April 
2018. The final release of the amended approval was received, and the purchases for the 
materials and consumables were requested. See appendices I and II for further details of the grant 
(budget), and ethical approvals. 
 
The plan of investigation is shown in Figure 7. 
2.1.3. Data Collection 
Data were retrospectively collected from medical records for all patients attending and followed 
up in the adult Immunology Clinic, Hamad Medical Corporation Qatar, over the last ten years. All 
patient records that fulfil the criteria for primary immunodeficiency were reviewed. The patients’ B-
cell phenotypes and complications associated with each disease were further characterised. 
 
2.1.4. Patients Recruitment 
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A cohort of 10 patients affected by PIDD (Predominantly (B-cell) antibody or combined 
immunodeficiency), with a focus on CVID and SAD, attending the Unit of Adult Allergy and Clinical 
Immunology at Hamad Medical Corporation, Qatar were included. PIDD (CVID and SAD) 
diagnosis was based, with a minor modification, on the ESID 2017 criteria. The post-vaccination 
poor response was defined as anti-pneumococcal polysaccharide antibody level that did not reach 
a level of 0.35 µg/mL after vaccination in 50% or more of the serotypes. The following criteria were 
used to diagnose CVID: low IgG levels (less than 2 SD below the mean for patients' age), and low 
IgM or IgA. In addition, the involvement of any of the following was used: an onset of 
immunodeficiency after two years of age, poor response to vaccines or the exclusion of other 
defined causes of hypogammaglobulinemia82-83. For SAD, criteria for diagnosis include a 
combination of the following: Infections (recurrent or severe bacterial, normal serum/plasma IgG, 
A and M and IgG subclass levels, profound alteration of the antibody responses to S. pneumoniae 
(or other polysaccharide vaccine) either after documented invasive infection or after test 
immunisation and the exclusion of T cell defects83. Inclusion criteria were immunologist-diagnosed 
PIDD (Predominantly (B-cell) antibody or combined immunodeficiency), age range 12-65 years, 
patients with PIDD who have been followed up for at least the last three months, and non-smokers 
over the previous eight weeks before the intervention. Exclusion criteria included pregnant women 
and subjects suffering currently from certain terminal illnesses, for example, cancer (and on 
chemotherapy), and subjects who refused or were unable to give informed consent, for example 
due to the presence of other neuropsychiatric conditions, namely autism and mental impairment. 
Then, selected patients were contacted by telephone, and an appointment was made. Patients 
were evaluated clinically during the clinical visit (Figure 8). As this was a proof of concept study, a 




Figure 8: Flow chart of the patients’ selection and recruitment. 
For stage 3 (interventional study), the scheme of steps that were followed is shown. 
 
Accessible population:  
Adult and children with 
PIDD in tertiary hospital  
Target population:  
All adult and 
children with PIDD 
in the community  
Scheduling three Clinic 
Visits 
Phone call to arrange 
appointment 
Flow chart for the recruitment strategy 
Applying questionnaires:  
Dietary 
well-being and symptoms 
Inclusion and exclusion criteria 
Selecting10 patients for the study 
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2.1.5. Designing the Questionnaires 
Dietary habits, health, and wellbeing questionnaires before recruitment were utilised to help to 
perform a subjective assessment of the study patients. A Symptoms Questionnaire was used to 
evaluate the patients’ symptoms and wellbeing before recruitment and as a measuring tool for 
reassessment during the study period. A Dietary Questionnaire was used to evaluate patients’ 
dietary habits before starting the study and to monitor any major changes in dietary habits that 
may affect the intervention step. The dietary questionnaire that was developed was based on the 
Harvard Food Frequency Questionnaire (for food habits). The wellbeing and symptom 
questionnaires that were developed was based on health quality SF6 and CH50 (for health and 
clinical stability)84-87. 
These Questionnaires were in English and translated into Arabic with validation of the translation 
by two expert physicians in the field of allergy and immunology, with an internationally accepted 
competency in English. Retranslation into English was done to confirm the accuracy of the 
translation. Validation of the questionnaires was done using a standardized procedure which 
included pilot-testing in the allergy and immunology unit for different types of patients, followed by 
psychometric validation by asking the participants to answer the questionnaire twice, to assess 
test-retest reliability. Also, the symptom questionnaire was applied for selected patients during the 
development of sickness (Figure 9). It was estimated that 40 minutes was needed to conduct the 















2.1.6. Participants and Samples Collections  
2.1.6.1. Blood and stool samples 
Patients with the diagnosis of PIDDs and fulfilling the inclusion criteria were investigated: Ten 
patients were selected for the diagnosis of humoral PIDD. Blood and stool sample collections were 
performed on four occasions over the study period: 1st sample before introducing IGIV, 2nd sample 
before vitamins interventional step, 3rd sample after the eight weeks of intervention, and 4th sample 
6-8 weeks after stopping the intervention. Other blood samples were collected to evaluate vitamin 
levels as part of the usual care and repeated once during the interventional step and if patients 
developed any new symptom that suggested vitamin toxicity. Vitamin medication was considered 
a safe treatment. In case the blood test was suggestive of the presence of severe symptomatic 
vitamin deficiency, patients were provided with a proper management plan, including referral to 
an appropriate speciality to check for secondary causes and provide treatment. Other 
anthropometric measurements like weight (kg), height (m), BMI (kg/m2), BP (mmHg), and 
physiological markers including spirometry (FEV1, FVC, and FEV1/FVC) and FeNO were 
collected during the three visits. CBC, CMP, and lipids profiles were checked during the four visits 
(Figure 7). 
 
2.1.6.2. Interventional Step 
The patients were given an internationally accepted and recommended dose of multivitamin 
supplements for an eight-week duration (intervention period). Vitamin supplementation type: A, E, 
B & D tablets. Doses were: Vitamin A 30,000 IU & E 70 mg (combined tablet) once daily, vitamin 
B complex (B-1 thiamine 5 mg, B3 Nicotinamide (NAM) 20mg, B-2 riboflavin 2 mg, and B-6 
pyridoxine 2 mg) once daily & Vitamin D2 50,000 IU once weekly. Blood and stool samples were 
collected at each stage (Figure 7). 
 
2.2. Methods 
2.2.1. Retrospective Chart Review  
Clinical Data of patients with PIDD registered over the last 10 years, in the adult allergy and 
immunology clinic, Hamad General Hospital, HMC, will be reviewed from Cerner electronic and 
physical medical records. Ethical approval and fund were granted from HMC-MRC as described 




2.2.2. Laboratory work 
2.2.2.1. Samples collection and processing 
Samples were collected in 3 different tubes (whole blood EDTA, Serum yellow-toped, and PAX 
gene tubes (Qiagen, Plymouth, UK)). A comparison was done between total and small RNA 
species extracted from serum exosomal, PAX tubes, and blood lymphocytes buffy coat with 
multiple trials to assess the best blood samples to be utilised for the study. Three extraction kits 
were used to compare the best quality of small RNA species extraction from serum exosome. 
(Appendix V) 
For microbiome DNA, two extraction kits were compared to identify the best kit producing good 
quality DNA for future extractions. Stool samples were collected in regular collection tubes and 
then transferred immediately upon receipt from patients to special OMNigene tubes (details 
below). Stool samples were stored at room temperature for a maximum of one week before 
extraction (may be kept at room temperature for up to 60 days). See Appendix (V) for the 
supplementary supportive initial experimental data. 
Whole blood samples were collected in yellow top vacutainer tubes (BD, SST™ Tubes contain 
spray-coated silica and a polymer gel for serum separation). Blood samples were left at room 
temperature for one hour to allow complete coagulation. Coagulated samples were then 
centrifuged at 2,000 rpm using SL 16R Centrifuge (Thermo Fisher Scientific Robert-Bosch-Straße 
1 D - 63505 Langenselbold Germany), for 10 minutes at room temperature to separate the serum. 
Serum was transferred to a new RNA free microcentrifuge tube with care taken to not disturb the 
buffy coat. Serum samples were immediately frozen at −80°C until exosome RNA extraction.  
2.2.2.2 Serum Exosome microRNA Extraction  
Different miRNA extraction methods from serum exosomes were evaluated with control serum 
samples. The extraction methods, mirVANA miRNA Isolation Kit (Ambion, Life Technologies, 
Thermo Fisher Scientific, Waltham, MA, USA), TRIzol Reagent (Invitrogen, Life Technologies, 
Grand Island, NY, USA), and TRIzol LS Reagent (Invitrogen), were tested with or without a carrier, 
ie glycogen (Invitrogen). Extractions were also performed using the miRNeasy Mini Kit (Qiagen, 
Valencia, CA, USA; see Appendix V). 
Extraction of exosome microRNA from serum was done using the Invitrogen extraction kit 
(Invitrogen, Life Technology, Carlsbad, CA, USA). Here, 500 µL of serum was used to precipitate 
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a pellet that was then re-suspended in 500 µL PBS. miRNA was extracted from exosomes 
suspension solutions by miRNeasy Mini Kit (Qiagen, Valencia, CA, USA), where 200 µL of the 
sample was used per extraction. 
2.2.2.3. Microbiome DNA Extraction from stool 
For stool samples, extraction of DNA was done using two extraction kits (QIAamp PowerFecal 
DNA Kit (Cat No./ID: 12830-50 and QIAamp Fast DNA Stool Mini Kit (50): 
51604 Qiagen Germany). Special collection tubes of stool were used (OMNIgene.GUT faecal 
collection kits; OM-200) to help with preserving the faecal samples for longer before extraction. As 
the extraction using QIAamp PowerFecal DNA Kit was of better quality, subsequent samples were 
extracted by this method only for running the array plates. A clean-up method using multiple 
ethanol washes and a heating step at 37ºC for a few minutes were added to improve the quality 
of the extracted DNA, as per the manufacturer’s requirements. See below for microbiome DNA 
quality assessment.  
2.2.2.4. Assessing the quality of serum exosomal miRNA and stool microbiome DNA 
2.2.2.4.1. miRNA Quality 
miRNA quantity and purity were assessed by spectrometric analysis using the Nano-drop 
(ThermoFisher Scientific NanoDrop™ 2000/2000c Spectrophotometers). RNA concentration and 
integrity were evaluated by the gel electrophoresis using the Agilent 2100 bioanalyzer (Agilent 
Technologies, Waldbronn, Germany). The samples that passed the above quality assessment 
tests were selected for further analyses. RNA with RIN > 6 were selected, while samples with RIN 
<3 were considered degraded, with miRNA sizes in the region 10-40 nt. The average size was 







Figure 10a: RNA integrity and concentration using Agilent bioanalysers.  






Small RNA (200 nt) were analysed by using kits from Agilent Technologies and chip technology. 
Fragments with a size of 15–40 nt were defined as miRNA (See figure below). The concentration 
of miRNA was calculated as absolute amount [pg] and as a percentage of small RNA [%]. (Figure 
10b). 





Figure 10b: Electropherogram for small RNA analysis. 
Example of electropherogram for small RNA analysis performed with the small RNA assay on the 
2100 bioanalyser (Agilent Technologies). 







2.2.2.4.2. Microbiome DNA Quality Assessment 
2.2.2.4.2.1. Genomic DNA for microarray 
Prior to the axiom assay, the quality of the genomic DNA was determined to be double-stranded, 
of high purity, free of DNA polymerase inhibitors (e.g. haem and EDTA), and salt-free to avoid 
inhibiting enzyme reactions. DNA purity was assessed by OD260/OD280 and OD260/OD230 
ratios. The OD260/OD280 ratio should be between 1.8 and 2.0 and the OD260/OD230 ratio should 
be greater than 1.5. A clean-up step was done to reach these required ratios. Microbiome quantity 
and purity was assessed by spectrometric analysis using the Nanodrop (ThermoFisher Scientific 
NanoDrop™ 2000/2000c Spectrophotometers) 
 
To ensure that the DNA was not degraded, the average size of gDNA was assessed by 
electrophoresis using 1% agarose gel and appropriate size standard controls. Approximately 90% 












Figure 10c: Agarose E-gel images of intact genomic DNA. 
Figure shows example of 1% agarose E-gel images of intact genomic DNA, suitable for use in the 
Axiom 2.0 Assay. Degraded gDNA was deemed not suitable for use. Approximately 90% of the 
DNA must be greater than 10 Kb in size.  








2.2.2.4.2.2. Fragmentation QC checks using 4% agarose E-gel 
During microarray preparation, Stage One of DNA amplification was followed by Stage Two of 
fragmentation, precipitation, and Stage Three of centrifuge and drying, resuspension and 
hybridisation preparation. Before proceeding to Stage Four of Denaturation and hybridisation, it 
was highly recommended to perform quantitation and fragmentation quality control checks at this 






Figure 10d: Agarose E-gel of fragmentation QC checks.  
Example of 4% agarose E-gel of fragmentation QC checks with the ladder used. Fragments should 
fall between 25bp and 125bp. 




Figure 10.0: Quality assessment of small RNA and genomic DNA. 
Figure 10a: RNA integrity and concentration using Agilent bioanalysers. 
Figure 10b: Electropherogram for small RNA analysis. 
Figure 10c: Agarose E-gel images of intact genomic DNA. 






2.2.2.5. Samples selection for microarrays 




2.2.2.6.1. Serum microRNA expression profiling using Array Plate 
The plate used in the microarray was Affymetrix® miRNA 4.1 24 Array Plate. The manufacturer’s 
instructions were followed in all protocols except for oven incubation, which was increased to 42 
hours, instead of 17 hours. 
2.2.2.6.1.1 Label Biotin: Affymetrix® FlashTagTM Biotin HSR RNA Labelling Kit to label the 
samples were used. A brief tailing reaction was followed by ligation of the biotinylated signal 
molecule to the target RNA sample (Figure 11). 
2.2.2.6.1.2 Hybridization protocol: Hybridisation was conducted according to the 
manufacturer's instructions as per the GeneChip miRNA 4.1 Human Array Plate/FlashTag™ 
Biotin HSR RNA kit (Affymetrix, ThermoFisher Scientific).  
2.2.2.6.1.3 Scan protocol: Arrays were scanned with GeneAtlas Imaging station scanner 
(Affymetrix, ThermoFisher Scientific). 
2.2.2.6.1.4 Data processing: The data was processed using Affymetrix expression console and 

















Figure 11: FlashTag™ HSR: Procedure overview.  
For analysis by Affymetrix GeneChip miRNA Arrays, it is essential to use a specific protocol for 
labelling total RNA or low molecular weight (LMW) RNA using FlashTag™ Biotin HSR Labelling 
Kit that includes a brief tailing reaction followed by ligation of the biotinylated signal molecule to 
the target RNA sample. The test takes less than one hour. 




2.2.2.6.2. Microbiome Arrays 
Different methods exist for microbiome sequencing. Three microbiome sequencing methods were 








Detect sequenced bacteria Y Y Y 
Detect sequenced viruses N Y Y 
Detect sequenced fungal, archaea, 
protozoa 
N Y Y 
Detect un-sequenced microorganisms Y (bacteria only) Y N 
Detect Functional genes N Y N 
Species resolution N Y N 
Strain resolution N Y N 
What is detected 16S rRNA gene Genome fragments Genome fragments 
Length of DNA detected (DNA bases) ~400 ~150-300 ~35 
Instruments 
Illumina MiSeq, Thermo 





Instrument cost ++ ++++ +++ 
Time on instrument (hours) 24-36 26-264 48 
Per-Sample reagent cost $30-50 $300-500 $40-50 
 
Table 4: Sequencing methods utilised in the literature to identify the human microbiome.  
Comparison between three methods: Axiom Microbiome Array, 16S rRNA sequencing, and the 
metagenomic sequencing. The Axiom Microbiome can detect as small as 35 DNA bases. It is 
unable to detect un-sequenced microorganisms when compared to the 16S rRNA sequencing and 
the metagenomic sequencing88. However, the Axiom Microbiome array is based on the recent 
sequence data and more probes per target compared to other microbial detection arrays, and it 
covers more bacterial and viral targets (Note: adapted from Thissen et al. 2019 88 and Gardner et 





Dilution of DNA samples was done to 5 ng/µL for human DNA samples in order to run the arrays 
according to the manufacturer’s requirements. The DNA extracted from faecal samples was 
applied to a microarray designed to detect all known microorganisms in a sample, with family-, 
species- and strain-level identification. Axiom™ Microbiome, 24 array plates, Catalogue number: 
902903, ThermoFisher Scientific was used for this purpose. See appendix VI (A-H) for procedure 









Number of target 
Sequences 
Archaea 31 370 606 
Bacteria 278  6,901 34,254 
Fungi  121 381 658 
Protozoa 30 91 229 Protozoa 30 91 229 Protozoa 30 91 229 Protozoa 30 91 229 
Virus 100 4,770 99,808 
Total  560 12,513 135,555 
Table 5: Axiom™ MiDAS target sequence database.  
This table of Axiom MiDAS target sequence database is comprised of select entries exported from 
Lawrence Livermore National Laboratory’s KPATH pathogen surveillance pipeline and database 
(https://str.llnl.gov/str/April04/Slezak.html). The KPATH pipeline automatically and regularly 
checks public domain sequence repositories (e.g., NCBI) for new and relevant sequence entries 
and incorporates them into the database. Axiom MiDAS database contains KPATH records that 
were current as of October 2014. (Adapted from Axiom™ Microbiome Solution USER GUIDE 
Catalogue Numbers 902910, 902904, and 902903- Publication Number 703408. 













2.2.2.7. microRNA and microbiome Genetitan, Axiom MiDAS and transcriptome analysis 
console course training.  
(See appendix (VII) for training certificates) 
 
2.3. Statistical Analysis 
2.3.1. The clinical Data 
For stage one (retrospective chart reviews) and stage two (questionnaire-based cross-section), 
the results were presented as mean with standard deviation (SD) for normally distributed data, 
median with interquartile range (IQR) for skewed results and frequency (number and percentage) 
of participants as appropriate. For categorical variables, groups were compared using chi-square 
test, and the Fisher's exact test (two-tailed) replaced the chi-square in case of small sample size, 
where the expected frequency is less than 5 in any of the cells. Pearson’s and Spearman’s 
correlation coefficients were calculated to assess the correlation between parametric and non-
parametric variables respectively. Data analysis was performed using Statistical Package for 
Social Sciences (SPSS Chicago IL, USA) for windows version 25. The level of statistical 
significance was set at P<0.05 
 
2.3.2. Microbiome analysis 
Microbiome analysis was conducted using Axiom™ MiDAS, which is an analysis package for 
automated high-resolution genomic detection of microbial samples, designed for use with data 
generated from Axiom Microbiome Arrays. Axiom MiDAS performs single-sample analysis of CEL 
files from Axiom Microbiome Arrays and automatically generates a comprehensive analysis 
summary in a simple-to-use software package. High-resolution genomic identification of archaea, 
bacteria, fungi, protozoa, and viruses can be detected in complex microbial samples. 










For establishing the beta diversity: We utilized R Package (betapart) for microbiome: https://cran.r-
project.org/web/packages/betapart/betapart.pdf 
2.3.3. microRNA data analysis 
Transcriptome Analysis Console (TAC) Software was the program utilised to run miRNA analysis 
following running the samples on the microarray’s plates. The software includes the functionality 
of Expression Console (EC) Software, and allows array QC and data normalisation to be 
performed, along with statistical tests for differential expression, and focusing on genes or 
pathways of interest, exploring interactions between coding and non-coding RNA, interpreting 
complex alternative splicing events, linking out to publicly available annotations, and obtaining 









Figure 12: The analysis of miRNA by utilising TAC Software technology. 
TAC software that was used to perform results normalisation and statistical tests for the different 
expression of miRNA. 



































This is the first of two results chapters. This chapter summarises data related to the retrospective 
data collection and analysis of the patients of PIDD seen at Hamad Medical Corporation, Adult 
Allergy and Immunology Unit (stage 1) and results of the questionnaire-based cross-sectional 
study that was used to select patients for the intervention step of the study (stage 2) (Figure 7). 
The most recent classification of PIDDs was published in January 2018, by the International Union 
of Immunological Societies (IUIS) PID expert committee (EC), on Primary Immunodeficiency. The 
committee meets and publishes every other year a classification of the inborn errors of immunity 
(Formerly called PIDD)3. The IUIS divides the disorder into nine categories. The majority of 
patients were diagnosed in late adolescence to adulthood, as compared to those diagnosed in 
early life, and who have more severe monogenic forms, belong to the predominantly antibody 
deficiency (PAD) category (common variable immunodeficiency (CVID), immunoglobulin A 
deficiency (SIgAD), Specific antibody deficiency (SAD) and IgG subclass deficiency)90-91. The 
geographical location and ethnicity play a role in determining the prevalence and clinical 
characteristics of PIDD based on epidemiological studies and international registries. Factors such 
as parent consanguinity and dietary habits are pertinent to PIDD studies and so must always be 
evaluated. PIDD in the MENA countries was associated with the higher consanguinity in Arabic 
countries28.  
The complications of the PIDDs received particular attention, especially in CVID, to evaluate the 
different disease phenotypes, outcomes and survival rates. PIDD is associated with multiple 
complications like chronic or recurrent infections, inflammatory conditions, and a variety of 
haematological and autoimmune diseases. Immune thrombocytopenic purpura (ITP), and 
autoimmune haemolytic anaemia (AHA) are the most common with a frequency of 7.6% and 4.8% 
respectively in CVID. Also, cytopenia was found common in congenital immune deficiency as well 
as in antibody defects including CVID and SIgAD. Different mechanisms have been proposed to 
explain this association like the presence of defects in T-cell regulation, cytokine defects, abnormal 
apoptosis, and the abnormal production of immunoglobulins with autoimmune features92. Other 
reports stated that the respiratory system is the most frequent site of the clinical manifestations in 
PID and has the highest morbidity and mortality. Recurrent respiratory infections are often the first 
warning sign and may lead to death in up 45% of cases. The types of complications associated 
with the respiratory system include recurrent, severe, and persistent infections (sinuses, ears, 
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throat and lungs) and with opportunistic or unusual pathogens. Also, immune dysregulation (in the 
form of autoimmunity, allergy, and lymphoproliferative disorders), structural abnormalities like 
bronchiectasis, interstitial lung diseases, organising pneumonia, and pulmonary adenopathies, 
and malignancies. Hyper-reactive airway diseases is another consideration particularly in CVID 
and Selective IgA Deficiency (SIgAD) (15-45% of patients). These patients may present or have 
a concomitant history of asthma and other types of atopic disorders and the diagnosis is 
challenging. Finally, pulmonary complications of PIDD treatment with IGIV and/or transplantation 
are iatrogenic injuries to be added to the list of complications93. 
 
3.2. Aims of the study 
1. To evaluate the clinical and immunological phenotypes of PIDD patients in an adult 
immunology service and to evaluate the morbidity related to disease complications in order to 
reach a better clinical stratification of patients with PIDD. 
2. To investigate clinical and chemical biomarkers in the presence and absence of complications 
in patients with PIDD. 
 
3.1. Methods 
The materials and methods have been described in detail in sections 2.1.1–2.1.3, and sections 
2.1.5 and 2.2.1. Briefly, two research designs were conducted, and the results are summarised in 
this chapter. A retrospective chart review was conducted for 48 medical records of PIDD patients 
followed over the previous 10 years. The second part is a questionnaire-based cross-sectional 
study for 26 PIDD patients in adult allergy and immunology service in the tertiary service (Hamad 
General Hospital) in Qatar. The study received local ethical approval and a grant. Data were 
collected for demographic characteristics, disease details (clinical and chemical biomarkers) and 
associated complications. Two questionnaires were used to evaluate patients’ dietary habits and 
clinical stability (see Appendices III & IV). Ten patients were selected based on the questionnaires’ 
analysis to be included for interventional part of the study (stage 3; discussed in Chapter 4). 
3.2. Results: Retrospective data analysis 
3.4.1. Demographic and clinical characteristics of the study subjects 
The wide spectrum of immunodeficiency phenotypes were analysed based on the existing 
immunodeficiency defects and the IUIS classification. Forty eight patients (different 
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immunodeficiency disorders) registered at the adult Allergy and Immunology Unit, Hamad Medical 
Corporation, in Qatar over the last ten years were retrospectively analysed based on their 
demographic profile. There were 28 (58.3%) male and 20 (41.7%) female patients making a male: 
female ratio of 1.4. The age of patients ranged from 10 to 74 years, with a mean age of 24.3 years. 
Positive family history was observed in 21 (43.8%) patients and the parents of 7 (14.6%) patients 
were consanguineous. The majority of patients (n= 42, 87.5%) were of Arab ethnicity. In total, 26 
(54.2%) were diagnosed in adulthood and 44 (91.7%) developed at least one of the disease-
related complications (Table 6). 
For simplicity, patients with PIDD were divided into two groups; Humoral or B-cell PIDD and Other 
PIDD. Combined T and B-cell immunodeficiency (CID), with syndromic features and 
Predominantly Antibody (Production) Deficiency (PAD) constitute the humoral or B-cell PIDD 
(Category 2 and 3 of the IUIS classification). The Other PIDD group is composed of four IUIS 
categories (defects in intrinsic and innate immunity, congenital defects of phagocyte number, 
function, or both, complement deficiencies, and diseases of immune dysregulation). Refer to Table 
1 in chapter 1 for the IUIS classification. The most prevalent disorders were CVID (n = 9, 18.8%), 
SAD (n = 7, 14.6%), and XLA (n = 6, 12.5%) and hypogammaglobulinaemia (n = 6, 12.5%). 
Combining XLA and hypogammaglobulinaemia may give a higher estimated rate for this particular 
group of patients with very similar diagnosis 12 (25%). Among the 31 patients with PAD, CVID 
accounted for 9 (29%), SAD (n = 7, 22.6%), and XLA (n = 6, 19.4%) and hypogammaglobulinaemia 
6 (19.4%). In addition, combining XLA and hypogammaglobulinaemia may give a higher estimated 
rate for this particular group of patients with very similar diagnosis (n = 12, 38.7%). One case of 
complement system deficiency (C7 complement deficiency) is recorded in this cohort. Tables 7 










All PIDD  
n= 48 
P-value 
Age in years (mean ± SD 
(range)) 
25.94 ± 11.89  
(10-74) 
19.3 ± 3.55  
(14-26) 
24.29 ± 10.79 
(10-74) 
0.005 
Male (actual number (%)) 21 (58.3%) 7 (58.3%) 28 (58.3%) 0.999 
Body Mass Index (mean 
± SD (range)) 
23.53 ± 7.91  
(10.8-44.89) 
22.23 ± 4.83 
(15.1-30.47) 
23.03 ± 7.19 
(10.8-44.89) 
0.595 
Ethnicity Arab (actual 
number (%)) 
31 (86.1%) 12 (100%) 42 (87.5%) 0.220 
Parental consanguinity 
(actual number (%)) 
2 (5.5%) 5 (41.6%) 7 (14.6%) 0.007 
Smokers (actual number 
(%)) 
4 (11.1%) 0 4 (8.4%) 0.303 
Diagnosed at adult age 
(actual number (%)) 
24 (66.7%) 2 (16.7%) 26 (54.2%) 0.004 
Complications (actual 
number (%)) 
36 (100%) 8 (66.7%) 44 (91.7%) 0.002 
 
Table 6: Comparison between B-cell immunodeficiency patients and other PIDD groups. 
The table PIDD. Age in years, presence of complications and presentation at adult age are 
statistically higher in B-cell group (P<0.05). Parental consanguinity was statistically higher in the 
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CID with associated 
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Recurrent 
infections 
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6 XLA PAD 23.5 (14-340 6 
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PAD 20.5 (15-29) 5 
1 Other combined 









1 SIgAD PAD 39 1 
 
Table 7: Patients in the category of B-cell immunodeficiency reclassified based on IUIS. 
Thirty-six patients were included. Majority of PAD is dominating in the male with male: female ratio 
of 1.3. The exceptions are CVID, Iso. IgMD. and SAD. The most common presentation is recurrent 
infection followed by atopic diseases. AT: Ataxia Telangiectasia, CVID: Common Variable 
Immunodeficiency, XLA: X-Linked Agammaglobulinaemia, SAD: Specific Antibody Deficiencies. 
Iso. IgMD: Isolated IgM deficiency, SIgAD: Selective IgA Deficiency, HIES: Hyper IgE syndrome, 
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Table 8: Patients with other PIDD category based on IUIS classification.  
Twelve patients were included. Similar to table 7, most of PIDD disorders are dominating in male 
patients with a male: female ratio of 7:5. Although recurrent infection is dominating, the second 
important presentation is family history. 
 
IL-12Rβ1 def.: IL-12Rβ1 deficiency that leads to milder form of Mendelian susceptibility to 
mycobacterial disease (MSMD), CGD: chronic granulomatous diseases, Rab27 a def: 
RAB27A mutation associated with NK cell cytotoxicity deficiency, ALPS post BMT: 
Autoimmune lymphoproliferative syndrome post bone marrow transplantation, C7 def.: 




3.4.2. B-cell PIDD 
3.4.2.1. PIDD Prevalence 
The prevalence of different disease is calculated from the review of the data available in the adult 
immunology clinics of the tertiary hospital of Hamad General Hospital Allergy and Immunology 
service- Qatar (Figure 13). This is not a representative of prevalence of the disease across Qatar. 






Figure 13: Relative frequency of PIDD in adult immunology clinics in a tertiary hospital in 
Qatar. 
The distribution of the different PIDDs was similar to the global distribution. Predominantly 
Antibody Deficiency (PAD) was dominating, followed by Combined Immunodeficiency (CID), 
defects in phagocytes and diseases in immune dysregulation. The patients were followed over the 
last 10 years. 
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3.4.2.2. B-cell PIDD and complications 
Among the 48 patients in this study, 36 had B-cell or humoral immunodeficiency of different 
diseases subtype and different complications distribution. The most common complications, which 
were predominated amongst the 36 patients with mainly B-cell immunodeficiency, were recurrent 
infections (n= 36, 100%), bronchiectasis (n= 26, 29%) and allergy (n= 8, 9%). The highest rate of 
complications was observed in CVID (n= 24, 26.7%), SAD (n= 19, 21%), XLA (n= 13, 14.4%) and 
hypogammaglobulinaemia (n= 11, 12.2%). Moreover, the recurrent infections and bronchiectasis 
were dominating in the PAD commonest diseases (CVID and SAD). The allergy complication was 
dominating in the isolated IgM deficiency (Iso. IgMD) and SAD while sparing the CVID. Non-
infectious complications including autoimmunity and auto-inflammatory complications were 
present in patients with CVID and SAD and were spared in XLA and other 
hypogammaglobulinaemia patients. Auto-inflammatory complications in this cohort referred to 
lymphoproliferative and inflammatory complications that involve the gut (enteropathy), liver, lungs 
(intestinal lung disease and granuloma), and lymphatic hyperplasia. Malignancy is one of the most 
severe outcomes of the diseases and was diagnosed in three patients. One of these patients 
presented with Non-Hodgkin’s lymphoma (NHL), and bronchiectasis with a history of recurrent 
infections and severely low immunoglobulins. The patient was later diagnosed with CVID. The 
other two patients also had malignancies (leukaemia and lymphoma) and died during this study. 
The mortality was not present at the time of collection of these data. However, three patients died 
during the next stages of this research study; two were due to malignancies (mentioned above) 








Disease class based on 2017 IUIS phenotypic classification 
Class II: CID n= 5 Class III: PAD. n= 31 
Disease Name AT HIES 
Other 
combined 








Number of patients  3 1 1 9 6 7 6 1 2 36 
Recurrent infection 3 1 1 9 6 7 6 1 2 36 
Bronchiectasis 3 0 0 9 6 5 3 0 0 26 
Allergic diseases 0 1 0 0 0 3 1 1 2 8 
Auto-inflammatory 0 0 0 2 0 2 0 0 1 5 
Autoimmunity 0 0 0 2 0 2 0 0 0 4 
Malignancy 1 0 1 1 0 0 0 0 0 3 
Endocrinopathy 0 0 0 0 1 0 0 0 2 3 
arthritis 1 0 0 1 0 0 0 0 0 2 
Death 1  1    1   3 
Total number of 
complications 
9 2 3 24 13 19 11 2 7 90 
 
Table 9: Distribution of complications. 
Thirty-six patients with B-cell immunodeficiency were followed in Hamad Medical Centre, based 
on IUIS classification. 
The most common complication is recurrent infection, bronchiectasis and allergy. Autoimmunity 
include immune thrombocytopenic purpura, autoimmune haemolytic anaemia and autoimmune 
neutropenia. The three patients with malignancy: one with Leukaemia and two with lymphoma. 
Endocrinopathy includes thyroid disorders and diabetes mellitus. Auto-inflammatory includes 
lymphoproliferative and inflammatory complications that involve gut (enteropathy), liver, lungs 
(intestinal lung disease and granuloma), and lymphatic hyperplasia. AT: Ataxia Telangiectasia, 
CVID: Common Variable Immunodeficiency, XLA: X-Linked Agammaglobulinaemia, SAD: Specific 
Antibody Deficiencies. IgMD: Isolated IgM deficiency, SIgAD: Isolated IgA deficiency, HIES: Hyper 










Figure 14: Percentage distribution of complications. 






3.4.3. The correlation between clinical parameters in B-cell PIDD and the commonest 
complications 
Comparison is made between the different clinical parameters including IUIS classification (CID 
vs. PAD), parent consanguinity, ethnicity (Arabs vs. others), gender (male vs. female), smoking 
(smokers vs. non-smokers) and the age at which the diagnosis was first made (paediatric vs. adult) 
in the complications of bronchiectasis and allergy. (Figure 15 and 16). Age of presentation to 
health service was not a reliable indicator of the presence of multiple comorbidity or severe 
outcome. However, patients who presented in paediatric age group (<14 years old) had greater 
incidence of bronchiectasis in 11 out of 12 (91.7%) compared to those diagnosed at adult age 9 
out of 24 (37.5%) (P=.002). Gender and smoking were not associated with an increased rate of 
overall complications (P>.05). However, males were more likely to develop bronchiectasis than 
females (P=.003). Smoking, ethnicity and parent consanguinity were not associated with 
increased rate of bronchiectasis complications in this cohort (P>.05). For the complication of 
allergy, only the age of presentation was associated with statistically significant value. Patient 







Figure 15: The different clinical parameters in the complication of bronchiectasis. 
The complication of bronchiectasis is more represented among males and those diagnosed at 



































































































Figure 16: The different clinical parameters in the complication of allergy. 



































































































3.4.4. The correlation between the chemical biomarkers in patients with B-cell PIDD and 
the two complications of bronchiectasis and allergy 
The mean and median were computed for the chemical biomarkers in each one of the most 
common complications (bronchiectasis and allergy), to identify possible correlations. Tables 10 
and 11 summarise selected chemical biomarkers that are of clinical significance in many medical 
conditions with inflammatory and autoimmune complications. Those biomarkers were compared 
in the patients with PIDD who have complications to those who have not. 
Vitamin D was low in most of the patients (33 out of 36). However, the difference between patients 
with PIDD in both bronchiectasis and allergy complications compared to those with no 
complications for the vitamin D deficiency was not statistically significant (P>0.05). CRP and initial 
IgG level were statistically significant in the bronchiectasis and allergy complications groups 
(P<0.05). Mean and median of White Blood Cells (WBC) was statistically higher in patients without 







Initial IgG level @ 
diagnosis 
CD3 (count &%) 
Vitamin B12 IgA CD4 (count &%) 
S. folate IgM CD8 (count &%) 
RBC folate IgG1 CD19 (count &%) 
Vitamin A IgG2 CD3-, CD16+, CD56+ (count &%) 
Vitamin E IgG3 CD4/CD8 ratio 
WBC IgG4 Glucose 
Hgb TIgE HgA1C 
Plt IgG level (last) TSH 
Lymphocytes CRP C3 
Neutrophils (count&%) ESR C4 
Eosinophil (count&%) Ferritin AFP 
 
Table 10: Chemical and blood biomarkers as per medical records. 
Forty-eight patients were included in the retrospective study. WBC: White blood test, Hgb: 
Haemoglobin, Plt: platelets, Ig; Immunoglobulin, TIgE: Total IgE, CRP: C-Reactive Protein, ESR: 
Erythrocyte Sedimentation Rate, CD: cluster of differentiation (Lymphocytes cell co receptors and 
markers), HbA1C: Haemoglobin A1C (i.e. average levels of blood glucose over the last 3 months), 










bronchiectasis No bronchiectasis 
P-value 


















37.6 (50.2) 15.5 (6.5-67.1) 9.4 (14.0) 5.0 (3.3-8.2) 0.045 
ESR  
(mm/hr) 
20.1 (19.3) 14.5 (5.3-27.8) 16.4 (18.1) 11.5 (2.0-20.3) 0.374 
Ferritin (mcg/L) 61.9 (38.8) 
54.0 (26.8-
102.5) 
47.6 (41.2) 43.3 (7.0-74.8) 0.664 
WBC (x103/ul) 8.4 (3.5) 8.3 (5.8-9.2) 23.5 (68.2) 6.3 (3.9-8.8) 0.033 
Lymphocytes% 23.4 (16.1) 24.9 (6.9-34.4) 24.1 (16.5) 32.2 (5.5-36) 0.361 
HbA1C% 5.3 (0.5) 5.6 (4.8-5.7) 5.5 (1.5) 5.2 (4.8-5.3) 0.742 
TSH  
(mIU/L) 











Table 11a: The different chemical biomarkers in PIDD patients with the complication of 
bronchiectasis.  
Vitamins and acute phase reactants (CRP, ESR and Ferritin) were evaluated and compared in 
patient with PIDD with and without bronchiectasis complication. 
CRP: C-Reactive Protein, ESR: Erythrocyte Sedimentation Rate, WBC: White blood test, HbA1C: 
Haemoglobin A1C (i.e. average levels of blood glucose over the last 3 months), TSH: Thyroid-












Allergy No allergy P-
value Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Vitamin D 
(ng/ml) 













8.0 (5.1) 5.0 (5.0-15.0) 30.1 (45.1) 10.0 (5.0-38.0) 0.010 
ESR  
(mm/hr) 
14.9 (22.3) 3.0 (2.0-24.0) 19.4 (17.6) 16.0 (9.0-24.0) 0.120 
Ferritin (mcg/L) 34.4 (31.7) 24.5 (5.8-72.3) 61.5 (40.9) 58.8 (26.3-99.0) 1.000 
WBC (x103/ul) 40.8 (96.3) 8.6 (3.6-10.5) 7.8 (3.5) 6.7 (5.6-8.9) 0.543 
Lymphocytes% 18.5 (21.2) 6.2 (1.8-44.0) 25.2 (14.4) 28.5 (12.0-34.9) 0.580 
HbA1C% 5.8 (1.9) 5.0 (4.8-5.8) 5.3 (0.5) 5.3 (4.9-5.6) 0.964 
TSH  
(mIU/L) 












Table 11b: The different chemical biomarkers in PIDD patients with the complication of 
allergy. 
Vitamins and acute phase reactants (CRP, ESR and Ferritin) and other parameters were 
evaluated and compared in patient with PIDD with and without Allergy complication. 
CRP: C-Reactive Protein, ESR, WBC: White blood test, HbA1C: Haemoglobin A1C (i.e. average 







3.5. Results: Analysis of the two questionnaires 
Forty patients were enrolled onto the cross-sectional questionnaires study (stage 2). Two patients 
were withdrawn due to ineligibility (on nasogastric tube feeding), ten did not complete all 
components of the questionnaires and were removed, and two patients were excluded because 
of implausible serving intake. The cohort of 26 patients were included in the final analysis. 
 
3.5.1. Dietary questionnaire analysis  
Analysis of the dietary questionnaire was used to evaluate the servings of each food item per day 
and to identify correlation to the demographics of the patients (age and BMI). Also, it was done to 
evaluate dietary habits prior to intervention with vitamins.  
3.5.1.1. Demographic characteristics of diet intake of the patients with B-cell PIDD 
There was almost equal sex distribution with a mean age of 27.9. The mean BMI was 26.2. Most 
of the patients were taking enough servings of fruits (4.4) and vegetables (6.2). Those with 

















AGE (Mean +/- SD (range)) years 27.88 +/- 11.68 (15-60) 
Female frequency (%) 14 (53.8%) 


















































Dairy (Mean +/- SD (range))  
(servings/day) 
2.43 ± 2.34 (0-11.29) 
Fruit (Mean +/- SD (range))  
(servings/day) 
4.12 ± 4.41 (0-17.98) 
Vegetables (Mean +/- SD (range)) 
(servings/day) 
6.16 ± 3.26 (1.58-11.24) 
Cereals/seeds (Mean +/- SD (range)) 
(servings/day) 
2.92 ± 2.78 (0.22-13.01) 
Legumes/Nuts (Mean +/- SD (range)) 
(servings/day) 
0.66 ± 0.98 (0-3.75 
Meat (Mean +/- SD (range)) (servings/day) 2.26 ± 1.25 (0.08-4.93) 
Snacks (Mean +/- SD (range)) 
(servings/day) 
0.94 ± 0.97 (0-4.08) 
Sweets (Mean +/- SD (range)) 
(servings/day) 
1.09 ± 1.43 (0-7.24) 
Beverages/Alcohol (Mean +/- SD (range)) 
(servings/day) 
1.59 ± 1.78 (0-6.0) 
 
Table 12: Analysis of the dietary questionnaire. 





3.5.1.2. Correlation between dietary intake, age, and BMI 
Spearman's rho correlation coefficient was used to assess the relationships between age, BMI 
and dietary intake (Table 13). 
Spearman’s correlation analysis between age, BMI and the different dietary classes scores 
showed a negative correlation for sweet intake (r = -0.438 P<0.05). 
The sweets were negatively correlated to BMI. The Mean of the servings of sweet was 1 (range 
from 0-7; Table 12) indicating variable intake of sweets in the current cohort. Also, in Table 12, the 
intake of cereals meals was also of variable degree and can reach up to 13 servings. However, it 












r P-value r P-value 
Dairy -0.012 0.955 -0.247 0.224 
Fruit -0.378 0.057 -0.177 0.387 
Vegetables -0.228 0.263 -0.109 0.596 
Cereals/seeds -0.213 0.295 -0.032 0.875 
Legumes/Nuts -0.294 0.145 -0.213 0.296 
Meat -0.324 0.106 -0.191 0.35 
Snacks -0.228 0.263 -0.354 0.076 
Sweets -0.331 0.099 -0.438* 0.025 
Beverages/Alcohol 0.258 0.204 0.12 0.558 
*. Correlation is significant at the P<0.05 level (2-tailed). 
**. Correlation is significant at the P<0.01 level (2-tailed). 
 
Table 13: Correlation between dietary intake, age and BMI in patients with B-cell PIDD. 






3.5.1. Symptom questionnaire analysis 
The analysis of the symptom questionnaires helped to select clinically stable patients and exclude 
patients whose physical and mental health may interfere with the participation in the interventional 
part of the study (stage 3). A correlation analysis was performed between the symptoms and the 
patients’ demographics (age, sex and BMI) (Tables 12-17). 
 
3.5.2.1. Descriptive analysis of the general symptoms 
The most common symptoms were Compulsive eating (n = 25, 96.2%), discoloured lips (n = 25, 
96.2%), lack of energy with feeling of fatigue/sluggishness (n = 16, 61.5%), and cough (n = 13, 







Symptoms (n=26) Frequency n (%) 
DIGESTIVE TRACT  Nausea or Vomiting 6 (23.1%) 
Diarrhoea/ constipation 8 (30.7%) 
bloating feeling 11 (42.3%) 
Heart burn  7 (26.9%) 
Intestinal/stomach pain 7 (26.9%) 
EARS Itchy ears 4 (15.4%) 
Earaches 2 (7.7%) 
Drainage from ear 3 (11.5%) 
EMOTIONS Mood swings 11 (42.3%) 
Anxiety, fear or nervousness 5 (19.2%) 
Anger, irritability or aggressiveness 4 (15.4%) 
Depression 2 (7.7%) 
ENERGY/ ACTIVITY  Fatigue, sluggishness 16 (61.5%) 
apathy, lethargy 2 (7.7%) 
hyperactivity 2 (7.7%) 
Restlessness 5 (19.2%) 
EYES 
 
Watery or itchy eyes 9 (34.6%) 
Swollen, reddened or sticky eye lids 2 (7.7%) 
Blurred or tunnel vision 3 (11.5%) 
HEAD Head ache 10 (38.5%) 
Faintness 2 (7.7%) 
Insomnia 3 (11.5%) 
HEART  Irregular or skipped heartbeat 2 (7.7%) 
Chest pain 5 (19.2%) 
JOINTS/MUSCLES Pain or aches in joints 10 (38.5%) 
Arthritis 3 (11.5%) 
Pain or aches in muscles 7 (26.9%) 
Feeling of weakness or tired 7 (26.9%) 
CHEST Difficulty in breathing 5 (19.2%) 
Cough 13 (50.0%) 
MIND Poor memory 3 (11.5%) 
Confusion, poor comprehension 3 (11.5%) 
Difficulty in making decision 4 (15.4%) 
Learning disabilities 2 (7.7%) 
NOSE Stuffy nose 8 (30.8%) 
Sinus problem 9 (34.6%) 
Sneezing attacks 4 (15.4%) 
SKIN Swollen/discoloured tongue, gum or lips 25 (96.2%) 
Hives, rashes or dry skin 5 (19.2%) 
Hair loss 12 (46.2%) 
WEIGHT  Binge eating/drinking 3 (11.5%) 
Excessive weight 5 (19.2%) 
Compulsive eating 25 (96.2%) 
Under weight 5 (19.2%) 
OTHER Frequent illness 5 (19.2%) 
Genital itch or discharge 2 (7.7%) 
Table 14: Frequency of common symptoms in patients with PIDD. 




3.5.2.2. The Well-being Questionnaires 
These questionnaires were adapted from SF-6D86 and GHQ1287 to evaluate the patients’ general 
health and mental health prior to enrolment in the interventional part of the study. We were able 
to select 10 of the 26 patients, evaluated by these questionnaires, for stage 3 (intervention with 
vitamins) of the study. Those with functional limitations or mode instability, based on these 
questionnaires results, were excluded from the study selection for the intervention stage. Stage 3 
of the study and the analysis of these 10 patients is explored in chapter 4.  
 
Among the 26 patients, 23 patients had god quality of life with minimal pain or limitation in daily 
physical activities based on SF-6D quality of life questionnaire. Moreover, GHQ12 mental 
questionnaire revealed normal mental status in almost all patients with no evidence of depression 





SF-6D (Quality of life Questionnaire) 




Your health does not limit you in vigorous activities 12 (46.2%) 
Your health limits you a little in vigorous activities 12 (46.2%) 
Your health limits you a little in moderate activities 2 (7.7%) 
Your health limits you a lot in moderate activities 1 (3.8%) 
Your health limits you a little in bathing and dressing 3 (11.5%) 
Your health limits you a lot in bathing and dressing 1 (3.8%) 
ROLE 
LIMITATION (RL) 
You have no problems with your work or other regular daily activities as a result of your 
physical health or any emotional problems 
18 (69.2%) 
You are limited in the kind of work or other activities as a result of your physical health 3 (11.5%) 
You accomplish less than you would like as a result of emotional problems 2 (7.7%) 
You are limited in the kind of work or other activities as a result of your physical health 





Your health limits your social activities none of the time 15 (57.7%) 
Your health limits your social activities a little of the time 7 (26.9%) 
Your health limits your social activities some of the time 1 (3.8%) 
Your health limits your social activities most of the time 3 (11.5%) 
Your health limits your social activities all of the time 0 (0%) 
PAIN (P) 
You have no pain 9 (34.6%) 
You have pain, but it does not interfere with your normal work (both outside the home 
and house work) 
8 (30.8%) 
You have pain, that interfere with your normal work (both 
outside the home and house work) a little bit 
5 (19.2%) 
You have pain, that interfere with your normal work (both 
outside the home and house work moderately 
3 (11.5%) 
You have pain, that interfere with your normal work (both 
outside the home and house work quite a bit 
0 (0%) 
You have pain, that interfere with your normal work (both 




You feel tense or downhearted and low none of the time 13 (50%) 
You feel tense or downhearted and low a little of the time 7 (26.9%) 
You feel tense or downhearted and low some of the time 2 (7.7%) 
You feel tense or downhearted and low most of the time 1 (3.8%) 
You feel tense or downhearted and low all of the time 0 (0%) 
VITALITY (V) 
You have a lot of energy all of the time 5 (19.2%) 
You have a lot of energy most of the time 9 (34.6%) 
You have a lot of energy some of the time 10 (38.5%) 
You have a lot of energy a little of the time 1 (3.8%) 
You have a lot of energy none of the time 1 (3.8%) 
 
Table 15: Analysis of symptoms in patients with PIDD based on SF-6D Questionnaire. 





GHQ-12 (Mental Health)  
Symptoms (Have you recently) (n=26) Frequency n (%) 
1. Been able to concentrate on what 
you are doing? 
Better than usual 6 (23.1%) 
same as usual 17 (65.4%) 
less than usual 1 (3.8%) 
much less than usual 2 (7.7%) 
2. Lost much sleep over worry? Not at all 12 (46.2%) 
No more than usual 10 (38.5%) 
Rather more than usual 2 (7.7%) 
Much more than usual 2 (7.7%) 
3. Felt you were playing a useful part 
in things? 
More so than usual 4 (15.4%) 
Same as usual 19 (73.1%) 
less useful than usual 1 (3.8%) 
Much less useful 1 (3.8%) 
4. Felt capable of making decisions 
about things? 
more so than usual 6 (23.1%) 
same as usual 17 (65.4%) 
Less useful than usual 2 (7.7%) 
much less capable 1 (3.8%) 
5. Felt constantly under strain? Not at all 9 (34.6%) 
No more than usual 13 (50%) 
Rather more than usual 2 (7.7%) 
Much more than usual 1 (3.8%) 
6. Felt you could not overcome your 
difficulties? 
Not at all 13 (50%) 
No more than usual 6 (23.1%) 
Rather more than usual 3 (11.5%) 
Much more than usual 1 (3.8%) 
7. Been able to enjoy your 2rmal day-
to day activities? 
More so than usual 3 (11.5%) 
Same as usual 19 (73.1%) 
Less so than usual 3 (11.5%) 
Much less than usual 1 (3.8%) 
8. Been able to face up to your 
problems? 
More so than usual 3 (11.5%) 
Same as usual 19 (73.1%) 
Less so than usual 3 (11.5%) 
Much less able 1 (3.8%) 
9. Been feeling unhappy and 
depressed? 
Not at all 13 (50%) 
No more than usual 9 (34.6%) 
Rather more than usual 4 (15.4%) 
Much more than usual 0 (0%) 
10. Been losing confidence in 
yourself? 
Not at all 18 (69.2%) 
No more than usual 5 (19.2%) 
Rather more than usual 1 (3.8%) 
Much more than usual 0 (0%) 
11. Been thinking of yourself as a 
worthless person? 
Not at all 23 (88.5%) 
No more than usual 1 (3.8%) 
Rather more than usual 1 (3.8%) 
Much more than usual 0 (0%) 
12. Been feeling reasonably happy, 
all things considered? 
More so than usual 3 (11.5%) 
About same as usual 20 (76.9%) 
Less so than usual 2 (7.7%) 
Much less than usual 0 (0%) 
Table 16: Analysis of symptoms in patients with PIDD based on GHQ12 Questionnaire. 
The majority of patients expressed normal mental health.  
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3.5.2.3 Correlation between symptoms questionnaire and the age, gender and BMI 
Pearson’s correlation coefficients were used to assess the relationship between Age, gender and 
BMI to symptoms (Table 17). 
Pearson’s correlation analysis between age, gender, and BMI and the different symptoms scores 
showed a negative correlation for the faintness, hair loss, perception of excessive weight, and 
frequent urination and a positive correlation with difficulty in making decision, and frequent 





Spearman's rho (n=25) 
symptoms 
AGE Gender BMI 
r P-value r P-value r P-value 
Faintness -0.041 0.846 -0.307 0.136 -0.409* 0.042 
Difficulty in 
making decision 
0.409* 0.042 -0.017 0.934 0.537** 0.006 
Slurred speech 0.523** 0.007 -0.236 0.256 0.416* 0.039 
Hair loss -0.247 0.244 0.251 0.237 -0.446* 0.029 
Binge 
eating/drinking 
0.453* 0.023 -0.384 0.058 0 1 
Excessive weight -0.035 0.869 -0.32 0.119 -0.402* 0.046 
Frequent illness 0.132 0.53 0.08 0.704 0.499* 0.011 
Frequent or 
urgent urination 
-0.041 0.846 -0.307 0.136 -0.409* 0.042 
Genital itch or 
discharge 
0.430* 0.032 -0.307 0.136 0.133 0.526 
*. Correlation is significant at the P<0.05 level (2-tailed). 
**. Correlation is significant at the P<0.01 level (2-tailed). 
Table 17: Correlation between the symptoms and age, gender and BMI in patients with B-
cell PIDD. 
Analysis using Pearson’s correlation (Only positively correlated symptoms were presented in this 
table). Symptoms such as neurological functions, excess weight, autoimmune hair loss and urinary 
tract infections showed a statistical correlation with the age and BMI (P<0.05). However, gender 






This chapter presented the retrospective data collected from the 48 patients of PIDD seen in 
Hamad General Hospital, Allergy and Immunology service that were followed for the last 10 years 
with focus on the aetiology and frequency of PIDD and associated complications. Analysis of the 
two questionnaires (the dietary and symptoms and well-being) conducted as a cross-sectional 
stage and the sub analysis of the selected ten patients with predominantly antibody deficiency that 
were recruited for the study in stage 3 as also presented briefly. 
The PIDD different diseases prevalence data was compared to the global prevalence estimated12 
(Chapter 1 Figure 1a), and found similarity in the frequency of PAD. The PAD has higher survival 
chances to adult age compared to other PIDD phenotypes. Moreover, the initial presentation of 
this specific category can be only in the adult age in some cases. These data support the 
recognition that PIDD is not only a paediatric disease. The change in life expectancy, improving 
health care, and the presence of milder phenotype variants that can survive to adult age with fewer 
disease affections and are therefore undiagnosed in childhood may explain why these patients 
presented in adult age. Also, the usual presentation of recurrent infections, autoimmunity and 
malignancy in the paediatric age group can be the focus of the treating physicians while the 
underlying PIDD was inconspicuous90. It is estimated that 25% to 40% of all types of PIDD are 
diagnosed in adult age91.  
Our results showed that the most common disease was PAD (n=31, 64.6%) which is comparable 
to those seen in the adult immunology service. SIgAD is low in our report (n=1, 2.1%), which is in 
contrast to that reported for various European studies (up to 50%94). However, similar rates were 
observed in Iran94, a country that is geographically close to Qatar and may therefore share a closer 
ethnic background. Amongst patients with Primary Antibody Deficiency, CVID, SAD and combined 
XLA and hypogammaglobulinaemia account for (n=9, 29%), (n=7, 22.6%), and (n=12, 38.7%) 
respectively in our data. CVID may affect 35% of individuals in USA13. Also, 195 CVID and 105 
agammaglobulinaemia cases were compared, and the median age of diagnosis was 9.5 and 4 
years, respectively95. The registration rate of CVID ranges from 0.1 (Russia) to 11 (Netherland) 
per million population, by country population with a very variable diagnosis at paediatric age (<18) 
ranging from 0% (Lithuania) to 100% (Russia and Poland, Georgia, Belarus, and Egypt) with a 
peak of symptoms in the 1st and 3rd decades of life and a diagnosis delay that can reach up to 9 
years. This indicates that CVID is a disease that can occur with a similar probability throughout 
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life and can explain the high rate of bronchiectasis in the CVID, possibly due to diagnostic delay96, 
14,47. In this report, (n=7, 78%) of CVID and (n=5, 17%) of hypogammaglobulinaemia were 
diagnosed in adult age.  
Severe combined immunodeficiency (SCID) is an emergency medical condition that requires 
urgent medical interventions like bone marrow transplantation. Most patients with this severe form 
are diagnosed and die in infancy if no effective treatment is received94. No SCID cases were 
present in this report as the cohort was collected from adult immunology clinics. Only (n=1, 2%) 
of complement system deficiency is recorded in our cohort. Internationally, the rate is variable and 
ranges from 0.3 (Japan) to 16.2 (Israel)28,97. As SIgAD has an asymptomatic presentation15, one 
patient of SIgAD was identified here. The prevalence of PIDD in this cohort is not a representative 
of the country prevalence as the data were collected from the adult immunology service. This fact 
explains the non-presence of SCID in our cohort. Moreover, some milder forms as well as patients 
who were above 14 years and continued to be followed up in paediatric departments were not 
included.  
In this study, the male: female ratio (M: F) was 1.4. The estimated ratio in Qatar is 1.398. In the 
MENA region, the M:F ranges from 1.1 to 228. Multiple studies conducted in Iran estimated the 
ratio to be 1.427, 4 to 197, and 1.7 to 1. In UK the estimated ratio is 1.122. The higher rate in the 
male gender can be explained by the sex difference in B-cell subsets and immunoglobulin 
distribution47. The global consanguinity rate is 1–9% while it is 20–56% in the MENA region28. The 
parental consanguinity was observed in (n=7, 14.6%) in this study, and although it is lower than 
the average in the MENA region, it continues to be higher than the global average.  
The complications reported in PIDD varies and can involve respiratory, musculoskeletal, 
cutaneous and gastroenterology systems97. The antibody deficiency is considered a very rare 
cause of bronchiectasis with estimation of 0.7%-2.4% (adult) and 2%–10% (paediatric) when 
studied done in respiratory services99. However, higher rate is observed when analysing data 
about bronchiectasis among PIDD patients. The rate of bronchiectasis was reported to be 42.2% 
(of the 192 CVID) and 32.2% (of the 102 agammaglobulinaemia)95. In this report, recurrent 
infections were the main presentation as well as the main complications and the rate of 
bronchiectasis was 100% in CVID and 50% in hypogammaglobulinaemia. 
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Among the clinical parameters that been evaluated in relation to the two most common 
complications; bronchiectasis and allergy in B-cell PIDD, it was found that the age of presentation 
to the health service was the most reliable indicator for both complications. The presentation in 
paediatric age group (<14 years old) was associated with higher rate of bronchiectasis (P=0.002) 
while allergy complication was higher in those presented in Adult age (P=0.023). This may infer 
that the severe phenotypes presenting in childhood with recurrent and more severe infections lead 
to earlier physician suspicion and a diagnosis of the underlying immunodeficiency. The 
presentation with symptoms suggestive of asthma and other allergic disorders that are common 
childhood disorders may cause physicians to skip the investigation of the possibility of 
immunodeficiency until adult age. Male gender was associated with a higher bronchiectasis rate 
than female (P=0.003).  
The blood chemical biomarkers were evaluated in B-cell PIDD in relation to those complications. 
Most of the vitamins examined did not show any association. A high level of vitamin D deficiency 
was found in the Ataxia-telangiectasia group 6/14 (42.8%) and CVID group 3/17 (17.6%)70. The 
same low level was observed in this study and vitamin D was low in 91.7% of B-cell PIDD. 
However, it was not associated with an increased rate of any of the complications. Human studies 
to evaluate dietary effects on immune systems are very limited. Also, most of these studies depend 
on the blood testing38,69.  
C-reactive protein (CRP) is a very strong biomarker. Commonly it raised during inflammation (e.g. 
rheumatoid arthritis), cardiovascular diseases, and infections by up to 1000-fold during tissue 
damage or disease progression; it then falls after the reaction subsides within 18-20 hours100. In 
our data, CRP and initial IgG level were statistically significant in both complication groups (P<.05). 
Moreover, the mean and median White Blood Cell (WBC) counts were statistically higher in 
patients without complications (P=0.033); this may indicate a lower infection rate in this group 
compared to the bronchiectasis complication group, possibly due to good immunological cell 
response showed by an increase in WBC number. An interesting observation of the results is that 
the elevated CRP was associated with bronchiectasis while it was associated with no allergy 
complications. The opposite was observed for the initial IgG, which was lower in the bronchiectasis 
complications and no allergy complications group. 
The questionnaires were conducted to help with the selection of patients for the interventional 
stage of the study. More than 48 types of bias can be faced when looking at the questionnaires 
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and their analysis101; the most important in our data are recall bias and the response fatigue due 
to long questionnaires. However, potential candidates were identified, and 10 patients were 
selected successfully. The analysis that was done showed equal gender distribution and that most 
of the patients adapted a healthy life style with the sufficient consumption of antioxidants: fruit and 
vegetables (mean ± SD) accounted for 4.12 ± 4.41 and 6.16 ± 3.26 of daily servings, respectively. 
Dominating symptoms were cough and fatigue, sluggishness and swing of the mood. However, 
most patients were leading an almost normal life (despite the chronicity of PIDD) similar to that of 
the healthy population based on the quality of life and mental health questionnaires. The 
Spearman’s correlation between diet compositions to age and BMI indicate distorted reverse 
relation between sweet intake and weight. There is no clear explanation for this identified 
phenomenon and it is possible that obesity was related to eating other food like snakes, cereals 
etc.; however, the relation was not shown to be statistically significant. The Pearson’s correlation 
analysis between age, gender, and BMI and the different symptoms scores showed and a positive 
correlation with difficulty in making decision, and frequent illnesses and a negative correlation for 
faintness, hair loss, perception of excessive weight, and frequent urination in relation to age and 
BMI. No symptoms were significantly correlated to gender. We believe this is a logical correlation 
and can be reported in any chronic disease, rather than just being specific to PIDD. 
The findings of this study have to be seen in light of some limitations. Despite the study cohort 
representing all patients registered over the last 10 years in adult immunology service in Qatar, 
the small sample size of patients (n=48) is considered a limitation to the generalisation of results. 
Also, the population in this study is not reflective of the total general population of PIDD as it is 
retrieved from adult immunology clinics in Qatar. In general, there are limited research studies and 
significant lack of awareness about adult PIDD. PIDD is a group of rare disorders, particularly in 
the adult population. It may be worth collecting more data in the future to examine PIDD in the 
adult population by doing different types of research, like conducting an epidemiological survey to 
identify the real prevalence in Qatar. Another future direction could be multicentre studies to 
evaluate the burden of PIDD disease in the adult populations. Another limitation to the study was 
using the questionnaires. It is well known that multiple biases can be faced when looking at the 
questionnaires, including cultural bias and other personal issues101. The dietary questionnaires in 
particular carry multiple biases and cofounding factors, including the use of closed-ended 
questions and recall bias that may affect the accuracy. Also, it takes a long time for patients, who 
are suffering from chronicity and multiple disease-related complications of PIDD because of the 
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long list of food items. However, it may be time-saving somehow compared to daily records and 
simple to use and to gather usual dietary intake and to have estimate for average dietary habits 
over long period of time. 
3.7. Summary 
Patients with recurrent episodes of infections should receive an evaluation of the immunologic 
system early to fill the gap in late diagnosis and consequently to improve the treatment of PIDD 
patients and reduce the infection rate and complications. Familiarising the paediatric and medical 
physicians about primary immunodeficiency disorders is challenging across the globe because of 
the disease rarity and the focus of most health academy and community on other more prevalent 
morbid diseases. However, it is highly mandated to incorporate the knowledge of PIDD into the 
practice of general practitioners and primary and first line care providers.  
Further specific and pertinent analysis of the interventional stage to investigate the possibility of 
diet change as an immunomodulator and a potential area to invest in during the care of patients 







































This is the second of the two results chapters. This chapter provides an overview of data gathered 
in relation to the gut microbiome and serum exosome microRNA laboratory work analyses of ten 
patients with predominantly antibody deficiency that were recruited into the study. The results 
before and after interventions with micronutrient supplementations and intravenous 
immunoglobulin administration were compared. 
Microbiome and microRNA received an interest as important controlling points in inflammation and 
are targeted alone or combined in multiple studies102-104 to help with understating the mechanisms 
of immunomodulation, inflammatory responses and autoimmunity103-104. The diet-microbe-
metabolite-host interactions are studies to unravel targets for potentially modulate inflammatory 
responses and autoimmunity105-107.  
microRNA (miRNA or miR) are shown to play important roles at different stages of the 
development of the immune system for both innate and adaptive immunity103 (Figures 17 & 18). A 
recent review found that microRNAs (miRNAs) are essential for B-cell homeostasis, and this area 
can be a promising for identifying biomarkers and therapeutic options to cure B-cell-related 
immune disorders108. Only a few studies have tried to determine the role of microRNA and 






Figure 17: miRNAs involved in the development and function of the innate immune system. 
(Note; adapted from Dai et al. 2011103).  
CMP: common myeloid progenitor, GMP: granulocyte-monocyte progenitor, PAMPs: pathogen-













Figure 18: miRNAs involved in the development and differentiation of adaptive immune 
system. 
(Note: adapted from Dai et al. 2011103).  
CLP: common lymphoid progenitor, CD4− CD8−: double negative (DN), CD4+CD8+: double 







4.2. Aim of the study 
1. To investigate the effect of supplementation with common micronutrients (multivitamins A, B, 
E and D), alone or combined with IGIV, on the serum exosome microRNA and gut microbiome.  
 
4.3. Methods 
Ten patients were selected based on the questionnaire analysis (see Chapter 3 section 2.1.4 - 
2.1.5 and 2.2.2). The selected patients fulfilled the inclusion clinical criteria for Predominantly 
Antibody Deficiency (CVID and SAD). The internationally recommended dose of multivitamin 
supplements: Vit-A, -E, -B & -D for an eight-week duration (intervention period). Serum exosome 
miRNA and stool microbiome were extracted and analysed. The blood and faecal samples were 
collected at three intervals; before, by the end of 8 weeks, and 6 weeks after stopping vitamin 
supplementation. 
 
4.4. Results: Demographic Characteristics of the 10 patients recruited into the 
interventional stage 
Written informed consent was obtained from all participants in the study. The study was approved 
by local Ethical Committee of the Hamad Medical Corporation, Doha, Qatar (MRC-01-17-029). All 
clinical investigations were conducted according to the principles expressed in the 1964 Helsinki 
declaration and its recent amendments. Demographic characteristics of the ten patients recruited 






# Age Diagnosis Maturation BMI smoking Sex Ethnicity 
P1 24 adult 16.66 no female Arab 
P2 14 adult 17.7 no male Arab 
P3 23 adult 20.83 no female Arab 
P4 21 adult 20.04 no female Arab 
P5 36 adult 28.26 no female Arab 
P6 34 adult 26.87 no female Arab 
P7 25 paediatric 17.08 no female Arab 
P8 43 adult 42.04 no male Arab 
P9 28 paediatric 18.9 no female Arab 
P10 26 adult 21.61 no female Arab 
 
Table 18: Demographic characteristics of the study population.  
Description of the 10 patients that were recruited into the interventional study. Patient sequence 
number was the same sequence number that been entered into array analysis of the microbiome 













antibiotics in the 






P1 SAD recurrent infections 
2 on prophylactic 
antibiotics short term 




4 on prophylactic 
antibiotics short term 
P4 SAD recurrent infections 4 2 short term 












4 on prophylactic 
antibiotics long term 









Table 19: Clinical parameters of the study population.  
Recurrent infections were presented in all patients. Four out of the ten patients were using 
Intravenous Immunoglobulin (IGIV) medication since childhood. The remaining 6 patients started 
to receive IGIV three months prior to collecting the second blood samples. The first blood samples 
were collected from those six patients before starting IGIV treatment. Patient sequence number 
was the same as that which had been entered into array analysis of the microbiome and microRNA 






4.5. Results: Microbiome 
4.5.1. Introduction 
Microbiome analysis was conducted using Axiom™ MiDAS.  
High-resolution genomic identification of archaea, bacteria, fungi, protozoa, and viruses can be 
detected in complex microbial samples.  





Microbiome data were analysed and expressed using alpha and beta diversity. The definition of 
each one and the results were given below in section 4.5.5 (alpha diversity) and section 4.5.6 
(beta diversity). 
 
4.5.2. Microbiome analysis plan 
Figure 25 and Table 20 summarised the analysis plan sample condition for the 44 microbiome 









Figure 19: Analytical plan of the microbiome faecal samples.  
Analysis of the microbiome (n= 44) faecal samples, representing 10 patients, for alpha and beta 
diversity analysis. The two positive and two negative controls used during running the array plate 

































P1 P1a_PreVit P1a_PostVit P1b_PreVit P1b_PostVit   4 
P2 P2a_PreVit P2a_PostVit P2b_PreVit P2b_PostVit   4 
P3 P3a_PreVit P3a_PostVit P3b_PreVit P3b_PostVit   4 
P4 P4a_PreVit P4a_PostVit P4b_PreVit P4b_PostVit   4 
P5 P5a_PreVit P5a_PostVit P5b_PreVit P5b_PostVit   4 
P6 P6a_PreVit P6a_PostVit P5b_PreVit P5b_PostVit   4 
P7 P7a_PreVit P7a_PostVit P7b_PreVit P7b_PostVit P7c-PreVit P7c_PostVit 6 
P8 P8a_PreVit P8a_PostVit P8b_PreVit P8b_PostVit   4 
P9 P9a_PreVit P9a_PostVit P9b_PreVit P9b_PostVit   4 
P10 P10a_PreVit P10a_PostVit P10b_PreVit P10b_PostVit P10c_PreVit P10c_PostVit 6 
DNA -C 2  2 
NTC 2 2 
Total 10 10 7 7 2  48 
 
Table 20: Microbiome conditions on the microarray 
All patients faecal sample were done in duplicate except P7 and P10 that were done in triplicate 
on the plate array. 22 samples and two (one negative and one DNA positive) controls were run in 





4.5.3. Microbiome Quality assessment 






Figure 20: The quality assessment of the integrity of genomic DNA for Genetitan 
application.  
The figure showed good and intact DNA. DNA must not be degraded. The approximate average 
size of gDNA was assessed on a 1% agarose gel using an appropriate size standard control. 
Approximately 90% of the DNA must be greater than 10 Kb in size. Refer to Figure 10C in chapter 







4.5.3.2. Microbiome DNA assessment using the Nanodrop 
Faecal microbiome DNA was assessed using Nanodrop reading after extraction, cleaning up with 
ethanol and heating att 37ºC. It showed good values that were acceptable based on the 
manufacturer’s requirements. Refer to chapter 2 (section 2.2.2.4.) for the utilisation of Nanodrop 
methodology and to appendix VIII for specific samples value of the Nanodrop reading.  
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4.5.3.3. Quality assessment during array preparation for fragmentation (QC checks using 
3% agarose gel) 
 
 
 Plate 1       Plate 2 
 
Figure 21: The quality assessment of the fragmentation QC checks.  
The quality of fragmentation was assessed using 3% agarose gel. During microarray preparation, 
stage one of DNA amplification was followed by stage two of fragmentation, precipitation, and 
stage three of centrifuge and drying, resuspension and hybridisation preparation. Before 
proceeding to Stage 4 of denaturation and hybridisation, a quantitation and fragmentation quality 
control check was carried at this stage using 3-4% agarose E-gel. Refer to Figure 10d of chapter 






4.5.3.4. Quantification of samples post-amplification and defragmentation and before the 
denaturation and hybridisation steps  
The Nanodrop was used to perform an assessment of the amplification and defragmentation step 
that should be done before proceeding to next step of denaturation and hybridisation. It is expected 
to achieve 120-fold mass dilution) 
It was found that this step was successful with all samples that reached 120-fold mass dilutions 
and allowed to proceed for next step in the microbiome protocol. Refer to appendix IX for detailed 







4.5.4. The Detected Targets 
4.5.4.1. Total Targets detected 
 
 
Table 21: Summary of the number of targets detected. 
The Axiom™ Microbial Detection Analysis Software (MiDAS) was used. The list summarised the 
three most discrete levels of taxonomic resolution.The table allows an 
initial analysis of each sample composition. 
In this summary table, reference to terminology is listed below: 
Sample Name: Name of the sample CEL file. Array Type: Microarray 
type. Number of Targets Detected: Number of targets in the algorithm 
model. Number of Species Detected: Number of species in the algorithm 
model. Number of Genera Detected: Number of genera in the algorithm model. Number of 
Families Detected: Number of families in the algorithm model. S: Sample. D: Replicate (duplicate) 
for the same sample. T: Replicate (triplicate) for the same sample. 
The number of families shown here only represent targets with known family assignments from 
the Axiom™ MiDAS database. 
(Analysis is based on Analysis of Axiom™ MiDAS results (chapter 4), Axiom™ Microbiome 
Solution. USER GUIDE. Catalogue Numbers 902910, 902904, and 902903. Publication Number 
703408. Revision 2.  
Adapted from thermofisher scientific website, accessed on 19/06/2019 
(https://assets.thermofisher.com/TFS-Assets/LSG/manuals/703408_Axiom-Microbiome-UG.pdf) 
S D T S D T S D T S D T S D T S D T S D T S D T
P1 53 58 53 57 48 53 46 51 34 36 32 35 13 14 13 16
P2 31 33 53 48 28 30 46 44 18 19 29 29 10 10 14 13
P3 51 52 57 52 45 43 47 43 30 30 33 29 19 20 19 16
P4 49 51 32 35 46 48 32 33 32 32 25 25 18 18 12 13
P5 58 53 40 39 44 40 32 30 23 23 19 19 15 15 13 14
P6 62 57 71 72 49 43 56 56 30 26 32 35 21 18 21 20
P7 32 43 40 31 36 33 26 36 33 29 33 32 22 26 27 20 21 20 13 20 19 13 13 13
P8 39 49 75 50 36 43 61 44 22 22 37 28 17 17 24 20
P9 48 44 49 57 42 39 44 52 30 28 36 41 19 18 21 21
P10 44 39 47 62 60 58 39 36 41 56 56 53 29 25 27 38 37 35 17 16 15 18 19 18
Number of Genera 
Detected
Pre Post Pre Post
Number of Families 
Detected









4.5.4.2. Families identified and those which disappeared after intervention 
Further analysis of the targets detected (by family’s name) that were observed to be changed by 




4.5.4.2.1. Families show-up after intervention 
 
Family Detected  P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 
Acidaminococcaceae   √                 
Bifidobacteriaceae   √               √ 
Coriobacteriaceae           √       √ 
Desulfovibrionaceae               √     
Enterobacteriaceae   √                 
Erysipelotrichaceae     √     √   √   √ 
Eubacteriaceae               √     
Lachnospiraceae               √     
Leuconostocaceae           √         
Micrococcaceae                   √ 
Oxalobacteraceae                 √   
Porphyromonadaceae               √     
Rikenellaceae               √     
Streptococcaceae   √                 
Veillonellaceae       √             
Myoviridae               √     
Unassigned bacteria               √     
Unassigned virus               √     
 
Table 22: Microbial families detected (show-up) only in the post-intervention samples. 
These were not present before intervention (micronutrients supplementation in pre-intervention 










4.5.4.2.2. Families not present after intervention 
 
Family Detected P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 
Bifidobacteriaceae         √           
Clostridiaceae     √ √     √       
Coriobacteriaceae     √ √             
Desulfovibrionaceae                   √ 
Enterobacteriaceae       √             
Eubacteriaceae             √       
Leptotrichiaceae               √     
Myoviridae       √             
Oscillospiraceae             √       
Oxalobacteraceae       √             
Podoviridae             √       
Prevotellaceae             √     √ 
Rikenellaceae             √       
Streptococcaceae         √           
veillonellaceae   √                 
Verrucomicrobiaceae       √   √         
Table 23: Microbial families not apparent post intervention. 
These were present before Intervention (micronutrients supplementation) in pre-intervention 
samples (both duplicates).  
 
Results Summary for Tables 22 & 23 
The tables summarise targets (families) identified in each patient. Family targets were found to be 
different in the post-intervention compared to pre-intervention samples. 
The erysipelotrichaceae family represented the most abundant microorganism post intervention 
out of those that were absent before and detected in the faecal samples after intervention (in 4 
patients). Patient 8 developed more than the other patients (9 new organisms) that were not 
observed before the intervention. In contrast, the Clostridiaceae family represented the most 
abundant microorganisms that were present before and after the samples are feft after intervention 
(in 30 samples). Patient 4 & 7 lost more than other patients (6 new organisms) that were detected 




4.5.4.3. Microbe Frequencies 
Figures 28 and 29 summarise the commonest 35 microbes’ frequencies based on the species and 







Figure 22: Frequencies based on detected targets microbial species. 









Figure 23: Frequencies based on detected targets of microbial families. 




4.5.5. Alpha Diversity  
For the alpha diversity, the observed alpha diversity was used 
(https://drive5.com/usearch/manual/alpha_diversity.html)110 which measures how many targets 
(bacteria or viruses presented in this sample) 
The terms alpha and beta diversity were introduced by R.H. Whittaker in 1960.  
Alpha diversity is the diversity in a single ecosystem or sample. The simplest measure is the 
species richness, the number of species (or OTUs) observed in the sample. It is the answer to the 
question how many different species could be detected in a microbial ecosystem? So, species 
richness is the number of different species in a sample. Practically, we count the number of 
distinguishable taxa (OTU's) in each sample. 
Other metrics consider the abundances (frequencies) of the OTUs, i.e. the proportion of a species 
in a community. For example, to give lower weight to lower-abundance OTUs. Axiome microbiome 
is a sequencing array which is not able to give abundances. Also, evenness that is how well a 
species represented is another index to measure alpha diversity110. Appendix X give details 
about commonly used diversity metrics  










Figure 24: Alpha diversity in patients with PAD after vitamin supplementation.  
Analysis was done for all samples, pre- vs. post-intervention with vitamins supplements. The 
results were presented in median, quartiles, and range. The comparison was made by using t-
test. Any box plot shows significant p-value, is marked as *** <0.001, ** <0.01, * <0.05.  
Results Summary: There was no significant difference in the observed diversity. However, the 










4.5.5.2. Alpha diversity comparing patients received short term (IGIV for the last three 












Figure 25: Alpha diversity in patients with PAD after short-term IGIV. 
Analysis was done to compare pre- vs. post-intervention with vitamins supplements in the 
subgroup of patients that were in short term IGIV. The results were presented in median quartiles 
and range. The comparison was made by using t-test. Any box plot that showed significant p-
value, is marked as *** <0.001, ** <0.01, * <.05.  
Results Summary: There was no significant difference in the observed diversity. The Post samples 
diverse almost equal to Pre samples diverse. In reviewing the medical and blood tests as well as 











Figure 26: Alpha Diversity in patients with PAD after long-term IGIV. 
Analysis was done to compare pre- vs. post-intervention with vitamins supplements) in the 
subgroup of patients that were in long-term IGIV. The results were presented in median quartiles 
and range. The comparison was made by using t-test. Any box plot shows significant p-value, is 
marked as *** <.001, ** <.01, * <.05.  
Results Summary: There is no significant difference in the observed diversity. The Post samples 








4.5.6. Beta Diversity 
For all the Beta diversity the (http://rfunctions.blogspot.com/2016/08/measuring-and-
comparing-beta-diversity.html)111 was used for definition. 
Beta diversity cab be defined by asking how different is the microbial composition in one 
environment compared to another. So, it is the diversity in microbial community between 
different environments (difference in taxonomic abundance profiles from different samples). 
Two metrics can be utilized to measure the beta diversity: Sorensen Index (also known as Bray-
Curtis) and Jaccard Index111.  
Sorensen’s Index is a measure that is very similar to the Jaccard measure. Sorensen and 
Jaccard coefficients are very closely correlated111.  
Jaccard distance is based on the presence or absence of species (does not include 
abundance information). It can be defined as the different in microbial composition between 
two samples where 0 means both samples share exact the same species and 1 means both 
samples have no species in common111.  




































Figure 27: Beta Diversity in patients with PAD after vitamin supplementation. 
Analysis was done of all samples, pre- vs. post-intervention with vitamin supplements. The results 
were presented in median, quartiles, and range. The comparison was made by using t-test. Any 
box plot shows significant p-value, is marked as *** <0.001, ** <0.01, * <0.05.  
Results Summary: There is no significant difference in the observed diversity. However, the Post 
samples were more diverse than the pre samples by both Jaccard and Sorensen. More diverse 










4.5.6.2. Beta diversity comparing patients received short term (IGIV for the last three 












Figure 28: Beta diversity in patients with PAD after short-term IGIV. 
Analysis was done to compare pre- vs. post-intervention with vitamins supplements in the 
subgroup of patients that were in short-term IGIV. The results were presented in median quartiles 
and range. The comparison was made by using t-test. Any box plot shows significant p-value, is 
marked as *** <0.001, ** <0.01, * <0.05.  
Results Summary: There is no significant difference in the observed diversity. The Post samples 
diverse almost equal to Pre samples diverse. In reviewing the medical and blood tests as well as 




























Figure 29: Beta diversity in patients with PAD after long-term IGIV. 
Analysis was done to compare pre- vs. post-intervention with vitamins supplements in the 
subgroup of patients that were in long-term IGIV. The results were presented in median quartiles 
and range. The comparison was made by using t-test. Any box plot shows significant p-value, is 
marked as *** <0.001, ** <0.01, * <0.05.  
Results Summary: There is no significant difference in the observed diversity. The Post samples 






n=4 (20 Samples) 
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4.5.7. Summary of microbiome results 
There were differences in the family targets of the gut microbiome between the different samples 
before and after interventions with some emerging and some disappearing. However, the gut 
microbiome was not able to show a significant difference in alpha and beta diversity. Further bigger 
sample size may be needed in the future to identify the potentially present differences. Also, 
utilising different microbial sequencing methods particularly by using metagenomic sequencing 
may provide more detailed and different results. Further analysis using different sequencing 
methodology and bigger sample size may be planned for the future microbiome analysis. 
 
4.6. Results: miRNA Analysis 
4.6.1. Introduction 
Transcriptome Analysis Console (TAC) Software was the program utilized to run miRNA analysis 
following running the samples on the microarray’s plates.  




microRNA (miRs) regulate more than 60% of human protein-coding genes112. Also, miRs not only 
grant precision to protein expression113, but may have many regulatory roles in various cellular 
processes and implicated in various diseases114. Circulating miRs account for over 100 and they 
may represent potential biomarkers of disease115. Serum or plasma miRs have been studied in 
cancer patients and their expression were up- or dysregulated compared to healthy subjects. 
miRNAs expression is dysregulated in human cancer through various mechanisms. Also, miRNAs 
may regulate the development of human tumours by acting as tumour suppressors or 
oncogenes116. Hornick suggested utilising circulating exosome miRs as novel minimally invasive 
biomarkers for acute myeloid leukaemia recurrence117.  
Nutrition is another identified factor that has complex relationship to miRs and gene targets. 
Macro- and micronutrients as well as newly identified dietary miRs may all participate in human 
diseases, its recovery and the healing process. Dietary miR database reported miRs in 15 dietary 
resources38, 112. Both endogenous mirRs and those derived from the diet have been expected to 
play a role in health and disease, particularly with regard to immune cell functioning during chronic 
inflammation and the fact that endogenous synthesis is altered by bioactive compounds in the 
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diet112. To the best of our knowledge, no data could be retrieved from the literature about circulating 
exosomal miR nor dietary effects on miR in PIDDs. 
This section of the study aimed to elaborate some of this complex relationship between circulating 
exosome miRs and dietary intervention and to find out any future potentials in the clinical practice 
for the patients suffering from B-cell immunodeficiency. 
 
4.6.2. Genes of interest in PAD 
In less than 10% of CVID patients, the disease is familial and may be attributed to monogenic 
defects with a predominantly autosomal dominant inheritance118-119. 
 
4.6.2.1. Reported monogenic genes in CVID: Total of 16 genes 
From the OMIM database: 13 genes: ICOS, TNFRSF13B, TNFRSF13C, CD19, CR2, MS4A1, 
CD81, IL21, LRBA, NFKB1, NFKB2, IRF2BP2, IKZF1119-120, We removed PRKCD gene that was 
described before119 from this list and replaced by IRF2BP2121. PRKCD was reported as a new 
defect for CVID122 (Previously labelled in OMIM as CVID, 9)120 associated with autoimmunity. 
Many authors continue to cite this gene under CVID. This was later removed and corrected 
following Oliveira’s123 review, showing that the picture was more towards Autoimmune 
Lymphoproliferative disorders (ALPS) rather than CVID. 
 
4.6.2.2. Genes reported in the literature to be associated with CVID 
The functions are mainly related to T-cell and B-cell defects leading to a deficiency in antibody 
production (Not reported in OMIM): 3 genes: CTLA4 and PLCG2 (Both cause a similar phenotype 
or modify the severity of the disease with comorbidities) and MSH5 (Regulation of Ig class switch 
recombination119. 
 
4.6.2.3. Extra genes that may be related to CVID: with OMIM number 
TNFSF12 (TWEAK) *602695, TNFRSF7 (CD27) *186711, IL21R *605383, PIK3CD *602839, 
PIK3R1 *171833, VAV1 *164875, RAC2 *602049, BLK *191305 2, PRKCD *176977120. 
 
4.6.2.4. Genes related to IgA deficiency 




4.6.2.5. Dietary resources for miRNAs124 
15 dietary products were found to have miRNAs that can be present in the human sera. 
 
Types Species 
Animal Human Breastmilk 
 Cow milk  
 Cow Fat 













Table 24: List of miRNAs identified in food components. 
The different types and species of dietary microRNA where mature and precursor miRNAs have 
been found based on Dietary MicroRNA Database (DMD).  




4.6.3. miRNA Analysis Plan 
 
 
Figure 30: Analytical plan for miRNA. 
Blood samples were collected from 6 patients who were naïve (never received any IGIV) and 4 
who had been on IGIV for a long time (since childhood). Second sample sets were collected from 




































P1 P1a_PreIg P1a_PreVit P1a_PostVit P1b_PreIg P1b_PreVit P1b_PostVit 6 
P2 P2a_PreIg P2a_PreVit P2a_PostVit P2b_PreIg P2b_PreVit P2b_PostVit 6 
P3 P3a_PreIg P3a_PreVit P3a_PostVit P3b_PreIg P3b_PreVit P3b_PostVit 6 
P4 P4a_PreIg P4a_PreVit P4a_PostVit P4b_PreIg   4 
P5 P5a_PreIg P5a_PreVit P5a_PostVit P5b_PreIg P5b_PreVit P5b_PostVit 6 
P6 P6a_PreIg P6a_PreVit P6a_PostVit P6b_PreIg P5b_PreVit P5b_PostVit 6 
P7  P7a_PreVit P7a_PostVit  P7b_PreVit P7b_PostVit 4 
P8  P8a_PreVit P8a_PostVit  P8b_PreVit P8b_PostVit 4 
P9  P9a_PreVit P9a_PostVit    2 
P10  P10a_PreVit P10a_PostVit    2 
RNA -C 2 2 
Total 6 10 10 6 7 7 48 
 
Table 25: miRNA conditions on the microarray. 
Ten samples were collected after IGIV and 10 after both IGIV and vitamin supplementation (7 had 
duplicates on microarray). Six samples were collected from patients at naïve status before any 





























Figure 31: Quality assessment of miRNA using Agilent bioanalyser. 
This chip offers one of the few possibilities to quantify miRNA. Fragments with a size of 15–40 nt 
were defined as miRNA. The concentration of miRNA was calculated as absolute amount [pg] and 
as a percentage of small RNA [%]. Please refer to Chapter 2 (section 2.2.2.4.1). 
 
 
The outcome results of extracted miRNA from the Genetitan were analysed by Transcriptome 




4.6.5. Summary of the results of miRNAs 
Comparison Group 1 Group 2 Count 1 Count 2 Up Down 
PostVit vs. PreIg PostVit PreIg 17 12 40 8 
PostVit vs. PreVit PostVit PreVit 17 17 2 1 
PreIg vs. PreVit PreIg PreVit 12 17 2 18 
 




Figure 32: Summary of miRNAs that were altered. 
PostVit vs. PreIg 
• PostVit: 17 samples, PreIg: 12 samples 
 
Filter criteria: 
• Fold Change: > 2 or < -2 
• P-val: < 0.05 
 
Total number of genes: 6631 
• Genes passed filter criteria: 48 (0.72%) 
• Up-Regulated: 40 (83.33%) 



























2.68 4.87 1.77 1.33 -4.56 0.002 0.364 chr2 
hsa-miR-
3148 
1.94 3.65 1.13 0.91 -3.28 0.002 0.364 chr8 
hsa-miR-
4793-3p 
2.38 4.22 1.49 1.6 -3.59 0.01 0.492 chr3 
hsa-miR-
4701-3p 
0.53 1.72 0.78 2.1 -2.27 0.03 0.586 chr12 
hsa-miR-
595 
0.4 2.07 1.07 1.86 -3.2 0.03 0.595 chr7 
hsa-miR-
185-3p 
0.27 2.2 1.22 1.7 -3.79 0.04 0.623 chr22 
hsa-miR-
1268b 
0.42 1.49 0.94 1.62 -2.09 0.04 0.646 chr17 
hsa-miR-
4763-3p 
1.18 2.5 1.12 1.01 -2.5 0.04 0.648 chr22 
  
Table 27: Dysregulated miRNAs.  
Eight miRNAs showed dysregulation after vitamin supplementation when compared to condition 





















hsa-miR-4497 7.16 3.01 0.66 2.55 17.75 1.71E-08 0.0001 chr12 
hsa-miR-122-5p 6.64 2.13 1.49 2.36 22.91 7.08E-06 0.0235 chr18 
hsa-miR-320d 5.61 3.39 1.12 1.82 4.67 3.44E-05 0.0723 chr13 
hsa-miR-320c 7.28 5.59 0.74 1.22 3.24 4.36E-05 0.0723 chr18 
hsa-miR-4429 4.62 2.37 1.53 1.12 4.78 0.0003 0.2093 chr2 
hsa-miR-320b 7.41 6.11 0.73 1.67 2.47 0.0005 0.2093 chr1 
hsa-miR-451a 6.34 3.76 1.49 1.45 6 0.0005 0.2093 chr17 
hsa-miR-92b-3p 4 1.17 1.87 1.32 7.1 0.0005 0.2161 chr1 
hsa-miR-320a 7.48 6.26 0.74 1.29 2.34 0.0007 0.248 chr8 
hsa-miR-486-5p 11.21 9.22 1.41 1.01 3.98 0.0009 0.2931 chr8 
hsa-miR-30d-5p 3.66 0.59 1.95 1.18 8.35 0.0014 0.3211 chr8 
hsa-let-7b-5p 8.12 7.06 1 0.67 2.09 0.0015 0.3489 chr22 
hsa-miR-92a-3p 10.75 9.42 1.23 0.83 2.52 0.0016 0.3613 chr13 
hsa-miR-4745-5p 2.22 0.2 1.71 0.86 4.05 0.0021 0.3642 chr19 
hsa-miR-22-3p 3.9 0.98 1.93 1.88 7.57 0.0025 0.3848 chr17 
hsa-miR-140-3p 5.29 1.86 1.89 1.71 10.82 0.0026 0.3848 chr16 
hsa-miR-150-5p 2.93 1.69 1.52 0.57 2.37 0.0029 0.4072 chr19 
hsa-miR-193a-5p 3.75 1.16 1.51 1.14 6 0.0031 0.408 chr17 
hsa-miR-3135b 2.59 0.39 1.97 0.98 4.61 0.0032 0.408 chr6 
hsa-let-7c-5p 6.35 5.2 1.41 1.39 2.22 0.0046 0.4121 chr21 
hsa-miR-25-3p 5.98 3.53 1.73 1.3 5.49 0.0068 0.4359 chr7 
hsa-miR-194-5p 1.7 0.36 1.67 0.35 2.54 0.0072 0.4433 chr1 
hsa-miR-423-5p 5.25 2.35 2.03 1.89 7.48 0.0077 0.4528 chr17 
hsa-miR-320e 1.85 0.59 1.85 0.33 2.39 0.0084 0.4649 chr19 
hsa-miR-652-3p 2.14 0.49 2.1 0.51 3.14 0.0084 0.4649 chrX 
hsa-miR-19b-3p 4.78 2.83 1.82 1.89 3.88 0.0106 0.5078 chr13 
hsa-miR-222-3p 2.98 0.99 1.63 1.47 3.99 0.0118 0.5189 chrX 
hsa-mir-484 2.34 1.06 1.65 0.42 2.42 0.014 0.5524 chr16 
hsa-miR-484 2.07 0.55 1.95 0.61 2.87 0.0172 0.5856 chr16 
hsa-miR-20b-5p 3.58 1.87 1.92 1.28 3.29 0.0193 0.5856 chrX 
hsa-miR-197-3p 4.3 3.24 1.11 1.25 2.09 0.0207 0.5856 chr1 
hsa-let-7i-5p 4.52 2.66 2.04 1.07 3.63 0.0207 0.5856 chr12 
hsa-miR-106b-5p 4.96 3.65 1.41 1.36 2.49 0.0267 0.5856 chr7 
hsa-miR-425-5p 5.16 3.78 2.02 1.7 2.6 0.0305 0.5948 chr3 
hsa-miR-6125 5.12 3.61 1.44 0.98 2.85 0.0351 0.6231 chr12 
hsa-miR-342-3p 4.02 2.35 1.67 1.45 3.17 0.0393 0.6394 chr14 
hsa-miR-660-5p 1.87 0.57 1.42 0.93 2.47 0.0426 0.6505 chrX 
hsa-miR-1246 4.74 2.12 1.57 0.98 6.16 0.0438 0.6551 chr2 
hsa-miR-151a-3p 2.19 0.76 2.06 1.01 2.7 0.0486 0.6693 chr8 
hsa-miR-4508 4.48 3 1.64 1.32 2.78 0.0488 0.6693 chr15 
 
Table 28: Up-regulated miRNAs.  
Only 2 showed statistical significance after correction of the p-value (FDR p-value). 
40 miRNAs showed up-regulation after vitamin supplementation when compared to the condition 







4.6.7. Volcano plot  
The miRNAs were presented by the Volcano plot diagram that plots significance versus fold-
change on the y- and x-axes, respectively. 
 
Figure 33: Volcano plot to quickly identify changes in large datasets. 
The grey TCs were those filtered out by the table. The green TCs were down-regulated while the 
red TCs were represented as up-regulated. If we switch the condition pair or the filter criteria in 
the table, the data in the graph will change accordingly. 
A volcano plot is a type of scatter plot. Volcano Plot graph plots significance versus fold-change 
on the y- and x-axes, respectively. The X-axis is the linear-fold change from the current condition 
pair; Y axis is -log10 P-value of the ANOVA P-values.  
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4.6.8. Venn Diagram 
Only the comparison between samples in the Post-Vitamins and Pre-IGIV conditions showed 





Figure 34: Venn diagram to identify the intersection of genes between comparison(s). 
Venn Diagrams based on Gene Lists was used to obtain common genes based on multiple 





































6.64 2.13 1.49 2.36 22.91 7.08E-06 0.0235  
chr12 
 
Table 29: Up-regulated serum miRNAs in peripheral blood of PAD following intervention. 























7.37 3.01 0.59 2.45 20.53 1.22E-06 0.0081 chr12 
 
Table 30: Up-regulated serum miRNAs in peripheral blood of PAD.  
This analysis was done following intervention in patients with similar clinical conditions regarding 








Figure 35: Principal Component Analysis (PCA) mapping.  
PCA plot, coloured by a custom user attribute, computes a set of linearly uncorrelated variables 
each of which is an orthogonal linear combination of the gene components. These variables are 
sorted to have decreasing variance. Retaining the top few components yields a reduced 
dimensional view of the samples that represents most of the variance among the samples. PCA 








4.6.11. Summary of the microRNA results 
In the present study, the microRNA (miRNA) expression profiles of patients with PAD before and 
after intervention with micronutrients were captured using microRNA array plate. 2 miRs (hsa-
miR-122-5p and hsa-mir-4497) had been identified to be up-regulated with the intervention step 
by multivitamin supplementation. Furthermore, bioinformatics analyses will be used to identify the 
genes and pathways, which were specifically associated with PAD and micronutrient intake-
associated miRNAs. Furthermore, the results require validation by Real-Time PCR (RT-qPCR) 
analysis as part of the future plan. 
 
4.7. Discussion 
In the current study, a dietary change is suggested to play an immunomodulatory effect on the 
miRNA and microbiome on patients with PIDD particularly PAD. This theory was never been tested 
before in PIDD patients. Few reports about associations of miRs (alone or combined with 
microbiome) to dietary intervention in malignancy either for miRNA received medical interest in 
colorectal and oral cavity cancers102,125. 
Few studies have suggested that miRNAs play a role in the inter-domain interaction between the 
gut microbiome and host and that this has an effect on symbiosis as well as on dysbiosis and the 
occurrence of illnesses. Three theories have been postulated which may explain, in part, this 
communication between the host, gut microbiome, and miRNAs; these are: (i) host gene 
expression is regulated by miRNAs, (ii) host miRNAs are influenced by gut microbiota, and (iii) the 
host miRNAs influences the gut microbiota126. 
In our study, the relationship between dietary intervention and the microbiome was not clear by 
alpha and beta diversities. However, the individual families showed some changes where some 
lost and some showed up after intervention. These changes in the detected families was not 
associated with any change in bowel behaviour or other symptoms. Any associated significance 
at this point could not be identified (outside the scope of the study) mainly because of the sample 
small size (a larger size is usually needed to see changes in the microbiome). Also, the short 
duration of the interventional step (8 weeks), and absence of follow-up of the microbiome in the 





Based on the miRBase Registry; www.mirbase.org127, around 1917 microRNAs have been 
identified in humans (homo sapiens). More than 2500 miRNAs have been described126, and 
around 2300 true human mature miRNAs, 1115 of which are currently annotated in miRBase V22, 
were estimated as the total number of true human miRNAs128. In our study, the total number of 
identified miRs was 6631, of which, 48 passed the filter criteria (40 up-regulated and 8 down-
regulated). Furthermore, two miRs (hsa-miR-122-5p and hsa-mir-4497) were identified to be up-
regulated when intervention with both IGIV and diet was performed. These two miRs will be 
discussed further in Chapter 5. hsa-mir-4497 was found to be associated with some B cells of 
interest: CD19, IL21, and PLCG2. hsa-mir-4497 was reported as one of the B cell miRs when they 
performed deep sequencing of the small RNA transcriptome of normal and malignant human B 
cells129. 
 
There are several important limitations of this study that could be addressed in future research. 
First, the study is focused on micronutrients and IGIV effects. We used multiple vitamins which 
were added on top of the regimen of regular IGIV and we assumed a synergistic effect; however, 
this is not been tested. Second, the sample size is small, and while it may be enough for the proof 
of concept, the results cannot be generalised and a larger sample may be required for similar 
studies. Because this study included patients with rare disorders, involvement of multiple 
immunodeficiency point of care centres may help to increase the sample size. The third is the use 
of microarrays. Microarray technology may provide a great opportunity for clinical and research 
work; however, multiple backwashes must be considered. The access and cost that can limit the 
current use as clinical tests, the number and quality of RNA and miRNAs extracted per sample, 
the need for cellular disruption to reach the genetic materials of interest and the general limitation 
of each microarray which can only provide knowledge about the genes that are present on the 
array130. Huge scientific evidence supports the use of microarrays despite these limitations88, 89, 125, 
126, 129. The final limitation is the short duration of the intervention step (8 weeks). Although it is not 
one of our main objectives, this duration is not sufficient to allow the observation of clinical 
improvement or worsening symptoms. All of these limitations do not undermine the quality and 
integrity of this research and the study was able to give some answers to the research question. 
The miRNAs identified in this study support the hypothesis of dietary influence on the complex 
communication between the gut microbiome and host via microRNAs and give a solid baseline for 
further workup and future investigation. Some direct beneficiary points that were performed but 
not discussed in this report include the fact that we identified some pathogenic organisms from 
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faecal samples using the microbiome arrays and we gave the patients the opportunity for a better 
clinical evaluation by requesting stool culture testing and providing proper antibiotics before the 
occurrence of clinical symptoms. 
 
4.8. Summary 
In this part of the study, although the gut microbiome did not reveal a significant difference in the 
diversity between the different intervention steps, the serum exosome microRNA uncovered two 
miRs which were up-regulated significantly after the interventions with vitamin supplementation 
and intravenous immunoglobulin administrations. One of these two miRs, hsa-miR-4497, was 
statistically significant, even when comparing the same conditions for the ten patients who were 
never exposed to IGIV before. hsa-miR-4497 was found to be associated with some genes of 
interest and this miR was reported previously with B cells129.  
Further validation using RT-qPCR analysis, followed by bioinformatics analyses to identify the 
genes and pathways, which are specifically associated with PAD and micronutrient intake-






















CVID and SAD share a lot of clinical similarities, and almost all have recurrent infections ranging 
from mild to severe autoimmune conditions, allergy and malignancy, similar to other PIDDs. 
Patients with CVID, IgG subclass deficiencies, selective IgA deficiency (SIgAD) and SAD share 
mutations in modifying genes, like the transmembrane activator and calcium-modulator and 
cyclophilin ligand interactor (TACI) gene. Furthermore, particularly in CVID/SIgAD families83, TACI 
has been suggested as a modifying gene which may be linked to states of defective class switch 
recombination, abortive plasma cell formation, and hypogammaglobulinaemia in response to 
BAFF and APRIL, which has received significant attention. TACI deficiency is also closely related 
to lymphoproliferation (like splenomegaly) and autoimmunity in mouse models118,131-140. Despite 
the focus of previous reports on proteotypic monogenic disorders with Mendelian inheritance, no 
unifying mechanism can explain the different spectrum of severity nor the correlation to clinical 
findings in patients with CVID and SAD. The most abundant group of PID patients (CVID and 
SAD) that received IUIS classification under the category of predominant antibody deficiency 
syndromes have mostly undefined genetic roots in more than 80% of patients.  
To clarify the underlying mechanistic pathways and to search for more precise clinical and 
prognostic factors, we investigate the relationship between the triad (the immunomodulatory effect 
of micronutrients, circulating exosome miRNAs and gut microbiome).  
 
5.2. Clinical Parameters 
The first part of this study evaluated the current data of patients with PIDD to identify any clinically 
relevant factor that can help with the re-clustering and re-stratifying of patients with PIDD with the 
aim to improve patient care and identify monitoring markers for this chronic illness. The second 
part investigates the possibility of dietary intervention with micronutrients (vitamins A, E, B and D)  
Common biomarkers continue to be of significant value in the clinical care of PIDD. The first was 
CRP, which is widely used in clinical practice. CRP is a homopentameric acute-phase 
inflammatory protein that was discovered in 1930 by Tillet and Francis during the working-up of 
patients suffering from Pneumococcus infection and it has a half-life of 19 hours100. Elevated CRP 
in this study was associated with bronchiectasis and no-allergy complications. This interesting 
observation of the results is logistical if we look at bronchiectasis as a process occurs in the context 
of chronic airway infection and inflammation141. Moreover, allergy in nature does not give rise to a 
CRP response142. The second inflammatory marker was WBC, which was high in patients without 
complications. This reverse relationship with WBC and bronchiectasis complications suggests that 
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bronchiectasis was higher in those whose body was unable to produce sufficient WBC to mount 
the infection thereby leading to increased infection and lung destruction (bronchiectasis). A study 
of 87 patients with bronchiectasis found significant associations between the HRCT bronchiectasis 
scores and elevated ESR, CRP, WBC and neutrophil count143. The third marker was the initial IgG 
level that were recorded in the clinics at establishing the diagnosis during first visits. The initial IgG 
levels were lower in the bronchiectasis complications and no-allergy complication group, indicating 
that the increased bronchiectasis complication was associated with a lower initial IgG. Also, this 
may suggest the level of confidence in the PIDD diagnosis without overlapping possibility for 
allergy based on the currently used international criteria in immunology clinics 83. 
Another important factor that was found to be correlating to bronchiectasis diagnosis in PIDD 
patients was the age of presentation to a medical service. It seems that presentation earlier in life 
may suggest a more severe phenotype and therefore additional bronchiectasis complication. 
 
5.3. Gut microbiome and miR signature in PAD 
We proposed that change in diet alters the nutrients available to microbiota resulting in the growth 
of some species and a change of microbiota composition. We identified some families with 
changes, but no significant relationship between gut microbiome alpha and beta diversity and 
dietary changes were observed. 
On the other hand, two miRs (hsa-miR-122-5p and hsa-mir-4497) were identified to be up-
regulated when an intervention with both intravenous immunoglobulin administration and diet was 
completed.  
 
hsa-miR-122-5p and hsa-mir-4497 in the literature  
When Searching for miRs in the literature, around 169 sources were identified, including miRbase, 
GeneCard, EntrezGene, OMIM, HGNG, Mastermind and others (GeneCards)144. 
hsa-miR-122-5p (accession number of MIMAT0000421) is located on chromosome 18 and has a 
sequence of UGGAGUGUGACAAUGGUGUUUG127. MIR122 (MicroRNA 122) is an RNA Gene, 
and is affiliated with the miRNA class. Diseases associated with MIR122 include non-alcoholic 
fatty liver disease and hepatitis C. Among its related pathways are MicroRNAs in cancer. Also, 
interacting proteins for the miR122 gene were represented by Gene Ontology (GO) (Biological 
Process for MIR122 Gene) as gene silencing by miRNA (GO:0035195) (GeneCard)144. 
159 
 
miR-122-5p has a tumour suppressor function through different molecular pathways. Seventy-one 
breast cancer patients were investigated to evaluate the expression profiles of miR-122-5p and its 
target ADAM10. ADAM10 expression was higher while miR-122-5p expression was lower in 
tumours than in normal tissue. It was proposed that miR-122-5p expression increases, especially 
in HER2+ cancer cells, to suppress ADAM10 shedding activity on HER2 receptors. miR-122-5p 
can function as a potential regulator of ADAM10 and help to overcome trastuzumab (monoclonal 
antibody used for breast cancer therapy) resistance and improve treatment outcome145. miR-122-
5p has effects on the proliferation, cell cycle and apoptosis of human melanoma cell lines SK-
MEL-110 and A375 and found that miR-122-5p expression is up-regulated in melanoma tissues. 
miR-122-5p inhibits the proliferation of SK-MEL-110 and A-375 cells possibly by affecting the cycle 
through NOP14 but has no effect on apoptosis146. miR-122-5p was also studied in 871 participants 
and found that the Levels of hsa-miR-122-5p and -885-5p were up-regulated in fatty livers and 
that both miRNA markers slightly improved the detection of fatty liver beyond the established 
risk factors. These miRNAs may be associated with fatty liver formation through the regulation 
of lipoprotein metabolism because hsa-miR-122-5p levels are associated with small VLDL, IDL, 
and large LDL lipoprotein subclass components147. Table 3 in Chapter 1 summarised some of 
the therapeutic development under clinical trials for miR-122 for hepatitis C virus infection. 
 




miR4497 (MicroRNA 4497) is an RNA Gene, and is affiliated with the miRNA class. Diseases 
associated with miR4497 include Scapuloperoneal Spinal Muscular Atrophy and Brachyolmia. 
(Gene cards) 144. miR4497 expression was down-regulated in laryngeal squamous cell carcinoma 
(LSCC) tumour tissues and cell lines compared to the normal counterparts. Overexpression of 
miR-4497 inhibits proliferation and induces apoptosis of LSCC cells, while down-regulating anti-
apoptotic Bcl-2 proteins. GBX2 is a direct target of miR-4497 when the mechanism was 
evaluated148. hsa-mir-4497 is considered one of the B cell miRs that were identified by deep 




As these were preliminary data, it is planned that by the end of this study we may reach an answer 
about the cross-talk between the triad that we hypothesised. Primary immunodeficiency disorders 
are currently clinically evaluated based on the single gene defect. We believe that there are 
potential areas for the discovery of the roles of other factors, like miRNA, diet immunomodulatory 
effects, and gut microbiota, which may influence the disease in these patients; this is an area that 
lends itself to personalised therapies, which can be enriched by the results from our study. 
5.5. Limitations 
Recruiting sufficient number of subjects with homogeneity in symptoms was a limiting factor in this 
study. Despite that, we believe that this was a reasonable number as the disease is considered 
rare. Furthermore, this research was planned as a proof of concept study. Depending on the 
results of this study, future multicentre collaborations may be needed to recruit sufficient numbers 
of patients for statistically significant results to inform detailed treatment modalities. 
 
5.6. Long-term future direction 
The current study aimed to re-stratify the patients with PIDD through the identification of novel 
markers or mediators in specific disease phenotypes (CVID and SAD). Further studies can follow 
this fundamental study, including functional research projects to look for further details about 
regulators, and can help to modify patient disease and the future developments of targeted or 
personalised therapies. In particular, miRNA-antagonised insertion or silencing with or without 
exosome transferring or transfection can function as cargo delivery to other mediators in these 
patients. Gut microbiome modification or transplantation is also another area of interest for many 
types of research that can be evaluated to help patients with PAD. 
 
5.7. Future Studies 
Further validation using RT-qPCR analysis on the current results and findings followed by 
bioinformatics analyses to identify the genes and pathways, which were specifically associated 
with PAD and micronutrient intake-associated miRNAs will be carried out to confirm microRNA 
signature changes and gene expression. Moreover, additional studies with larger sample sizes 
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APPENDIX I- The budget sheet summary & Requested Materials and Consumables 
The budget sheet summary. 
Budget Category 2018 Total Cost 
Travel & Conferences 2,000 2,000 
Materials & Consumables 153,504 153,504 
Total Cost 155,504 155,504 
The amount was in Qatari Riyals (around 34,421.58GBP). 
 











APPENDIX III- Food frequency questionnaire 
The Dietary Questionnaire modified from the Harvard Food Frequency Questionnaire (with 
addition of traditional Arabic food). Arabic translation was performed for Non-English 





























APPENDIX IV- Health & Clinical Stability assessment questionnaire 











APPENDIX V- Supplementary file (Experimental trials) 
1) Experiments performed to evaluate the best tests and kits to be utilised for the 
research project 
2. Blood sample analysis (initial results for the first 6 samples of patients (before IGIV) 
A. Total RNA 
1. Quantitative analysis using the Nanodrop analyser 


























III. Buffy coat (EDTA tubes) 
 
Interpretation: 
RNA purity can be measured photometrically using the Nanodrop. 
The optical density (OD) is measured at different wavelengths: 230 nm (absorption of 
contaminants and background absorption), 260 nm (absorption maxima of nucleic acids), and 280 
nm (absorption maxima of proteins). The OD260/280 ratio was used as an indicator of RNA purity. A 
ratio higher than 1.8 was assumed to be suitable for gene expression measurements. 
For our samples, there was no consistency in the results to assess for purity correctly. This was 
observed on the same instrument by different students and staff in an anti-doping lab. Therefore, 
we will mainly use the Agilent Bioanalyser.  
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Interpretation: RNA integrities were assessed using the Agilent Bioanalyser 2100 which 
calculates RIN values of assayed RNAs (table and figure above). The RIN is the computational 
output of an algorithm which ranks several parameters obtained from the electropherograms, 
assigning a numerical value to RNA integrity.  
 
The RNA integrity (RIN) for the first three samples (P1, P2 & P3) extracted using PAX tubes were 
above 7, indicating good quality total RNA. 
The electropherograms for the total RNA present two distinct peaks (28S, and 18 S) in patient 












Interpretation: RNA integrities were assessed using the Agilent Bioanalyser 2100 which 
calculates RIN values of assayed RNAs (Table and Figure above).  
The RNA integrity for buffy coat samples extracted by Trizol was above 7 for patient 6 only, 
indicating good quality total RNA. 
The electropherograms for the total RNA present two distinct peaks (28S, and 18 S) in patient 








Interpretation: (repeat attempt to assess the quality of the samples) 
RNA integrities were assessed using the Agilent Bioanalyser 2100 which calculates RIN values of 
assayed RNAs (table and figure above).  
The RNA integrity for buffy coat samples extracted by Trizol. None of the samples were above 7, 
indicating the absence of good quality total RNA. 
195 
 
The electropherograms for the total RNA present no distinct peaks (28S, and 18 S) in patient 
samples. This may suggest poor quality samples with degradation. 
 
B. Small RNA 
1. Agilent Bioanalyser 











Using SmallChip (Bio-SmallChip), data are shown for an exosome (the concentration in pg and 














Using SmallChip (Bio-SmallChip), data are shown for the buffy coat samples (the concentration in 






III. Blood samples analysis (results for an experiment to evaluate best extraction kit for 






















Using SmallChip (Bio-SmallChip), data are shown for an experiment comparing mirVana and 
Trisol extraction kits for buffy coat (the concentration in pg and percentage of small RNA and 






Summary of the results: 
Samples collected at baseline when the patients had not yet received IGIV. Extraction from 
different blood products was used to determine the best resource for the study, including whole 
blood (PAX tube), serum exosome and buffy coats. Multiple trials on control samples were also 
used to evaluate the best purification method with better yields including the use of Trizol and 
mirVana enrichment methods. Preliminary results from the six patients and from the different 
sources are promising. We managed to extract good quality RNA and small RNA from most of the 
samples. We noticed that using the Nanodrop for the readings was misleading and yielded some 
undependable results, while the Agilent analyser gave more consistent readings. We plan to 
primarily read all samples using the Agilent analyser. A few technical `issues are limitations, which 
will be corrected with the subsequent sample extractions. No microbiomes were used, so we 
currently have no data because the extraction kits had not been received when writing this report. 
The subsequent parts were done afterwards, when the extraction kits and arrays had arrived; the 
next steps were done when patients were on IGIV and multivitamins (interventional stage). 
 
 








2) Trials to assess best method for the extraction of miRNA from serum exosome and 
microbiome DNA from stool: 
 




Microbiome DNA extraction Nanodrop readings before and after the ethanol clean- up step 




# Sample ID Date and Time Nucleic Acid Conc. ng/µl A260 A280 260/280 260/230 Sample Type Factor
1 Repeat Nano reading Exp 1: microKit No DNase ص 08:01:16 12/11/2018 21.4 0.535 0.351 1.52 0.1 RNA 40
2 Repeat Nano reading Exp 1: microKit No DNase rem ص 08:02:47 12/11/2018 18.1 0.451 0.292 1.54 0.15 RNA 40
3 Repeat Nano reading Exp 1: microKit DNase ص 08:03:42 12/11/2018 9.2 0.23 0.141 1.63 0.11 RNA 40
4 Repeat Nano reading Exp 1: microKit DNase rem ص 08:04:20 12/11/2018 6.9 0.173 0.099 1.74 0.51 RNA 40
5 Repeat Nano reading Exp 2: microKit with homog ص 08:05:41 12/11/2018 17.6 0.44 0.299 1.48 0.67 RNA 40
6 Repeat Nano reading Exp 2: microKit no homo/ no Qiazol ص 08:06:37 12/11/2018 15.4 0.386 0.222 1.74 0.03 RNA 40
7 Repeat Nano reading Exp 3: microKit and serumkit: sample 1 il column ص 08:08:16 12/11/2018 76.2 1.906 1.314 1.45 0.19 RNA 40
8 Repeat Nano reading Exp 3: microKit and serumkit: sample 2  il column ص 08:08:56 12/11/2018 39.1 0.977 0.684 1.43 0.33 RNA 40
9 Repeat Nano reading Exp 3: microKit and serumkit: sample 3  j column ص 08:09:28 12/11/2018 30.5 0.763 0.515 1.48 0.16 RNA 40
10 Repeat Nano reading Exp 3: microKit and serumkit: sample 4  j column ص 08:10:00 12/11/2018 28.1 0.703 0.484 1.45 0.83 RNA 40
11 Repeat Nano reading Exp 3: microKit and serumkit: sample 5  micro column ص 08:10:34 12/11/2018 48.8 1.219 0.72 1.69 0.21 RNA 40
12 Repeat Nano reading Exp 3: microKit and serumkit: sample 8 micro column ص 08:11:03 12/11/2018 63.8 1.596 1.084 1.47 0.17 RNA 40
13 Repeat Nano reading Exp 3: microKit and serumkit: sample 9 micro column ص 08:11:33 12/11/2018 46.5 1.162 0.797 1.46 0.13 RNA 40
14 Repeat Nano reading Exp 4: invitrokit conc sample 1 ص 08:16:08 12/11/2018 7.8 0.194 0.106 1.83 0.04 RNA 40
15 Repeat Nano reading Exp 4: invitrokit conc sample 1 rem in gel ص 08:16:45 12/11/2018 18.7 0.469 0.055 8.56 0.24 RNA 40
16 Repeat Nano reading Exp 4: invitrokit conc sample 1 rem in column ص 08:18:33 12/11/2018 3.7 0.091 0.076 1.21 0.28 RNA 40
17 Repeat Nano reading Exp 4: invitrokit dil sample 2 ص 08:19:59 12/11/2018 2.5 0.063 0.022 2.92 0.03 RNA 40
18 Repeat Nano reading Exp 4: invitrokit dil sample 2 rem in column ص 08:21:09 12/11/2018 0.4 0.011 0.023 0.48 0.12 RNA 40
19 Repeat Nano reading Exp 4: invitrokit con sample 1 repeat nano ص 08:22:12 12/11/2018 6.7 0.168 0.089 1.87 0.04 RNA 40
# Sample ID User name Date and Time Nucleic Acid Conc. Unit A260 A280 260/280 260/230 Sample Type Factor
1st reading
1 sample 1 POWER WITH OMNI LAB م 02:56:32 17/07/2018 25.6 ng/µl 0.513 0.302 1.7 1.13 DNA 50
2 sample 2 POWER STOOL DIRECT LAB م 02:58:03 17/07/2018 66.3 ng/µl 1.326 0.764 1.74 0.99 DNA 50
3 sample 3 FAST OMNI LAB م 03:01:35 17/07/2018 74.1 ng/µl 1.482 0.791 1.87 1.23 DNA 50
4 sample 4 FAST STOOL DIRECT LAB م 03:02:43 17/07/2018 79.3 ng/µl 1.586 0.813 1.95 1.25 DNA 50
2nd reading
1 sample 1 conrtol powerfecal omni LAB ص 11:58:34 13/11/2018 43.4 ng/µl 0.868 0.483 1.8 1.6 DNA 50
2 sample 1 conrtol powerfecal omni LAB ص 11:59:36 13/11/2018 21.2 ng/µl 0.424 0.267 1.59 1.82 DNA 50
3 sample 1 conrtol powerfecal omni LAB م 12:00:04 13/11/2018 23 ng/µl 0.46 0.324 1.42 1.63 DNA 50
4 sample 2 conrtol powerfecal stool direct LAB م 12:00:51 13/11/2018 27.9 ng/µl 0.557 0.251 2.22 1.04 DNA 50
5 sample 2 conrtol powerfecal stool direct LAB م 12:01:22 13/11/2018 47.7 ng/µl 0.955 0.529 1.8 1.52 DNA 50
6 sample 3 Fast kit omni LAB م 12:06:22 13/11/2018 67.6 ng/µl 1.353 0.727 1.86 1.29 DNA 50
7 sample 4 Fast kit stool direct LAB م 12:07:17 13/11/2018 63.6 ng/µl 1.272 0.655 1.94 1.62 DNA 50
after clean up
5 sample 1 PF OMNI LAB م 02:55:48 13/11/2018 62.9 ng/µl 1.258 0.705 1.78 1.5 DNA 50
6 sample 2 PF stool LAB م 02:56:51 13/11/2018 60.9 ng/µl 1.217 0.662 1.84 1.85 DNA 50
7 sample 3 fast OMNI LAB م 02:57:42 13/11/2018 452.2 ng/µl 9.043 5.047 1.79 1.34 DNA 50
8 sample 3 fast OMNI LAB م 02:58:29 13/11/2018 461.7 ng/µl 9.233 5.137 1.8 1.34 DNA 50
9 sample 4 fast OMNI LAB م 02:59:12 13/11/2018 415.9 ng/µl 8.319 4.491 1.85 1.62 DNA 50
11 sample 4 fast stool LAB م 03:00:34 13/11/2018 414.7 ng/µl 8.293 4.471 1.85 1.63 DNA 50
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APPENDIX VI- Microbiome array methodology 
Microbiome array: 



















The protocol for manual target preparation composed of 















Stage 3: Centrifuge and drying, re-suspension and hybridisation preparation & QC 






























































APPENDIX VIII- Microbiome DNA assessment using the nanodrop 
Nanodrop quantification after extraction  





Nanodrop readings after extraction, cleaning with ethanol and heating @ 37ºC for 37 
samples of microbiome DNA. 
 
# Sample ID Nucleic Acid Conc. ng/µl A260 A280 260/280 260/230 Sample Type Factor Date and Time
1 microbiome P09 PQ-post heat @37 degree 8.5 0.169 0.152 1.12 1.1 DNA 50 م 04:13:43 20/11/2018
2 microbiome P10 PQ-post heat @37 degree 57.7 1.153 0.689 1.67 1.67 DNA 50 م 04:14:35 20/11/2018
3 microbiome P11 PQ-post heat @37 degree 109.4 2.187 1.174 1.86 0.87 DNA 50 م 04:15:24 20/11/2018
4 microbiome P11 PQ-post heat @37 degree 44.3 0.885 0.526 1.68 1.85 DNA 50 م 04:16:15 20/11/2018
5 microbiome P12 PQ-post heat @37 degree 13.3 0.266 0.171 1.55 2.39 DNA 50 م 04:17:10 20/11/2018
6 microbiome P12 PQ-post heat @37 degree 15.4 0.308 0.199 1.55 1.9 DNA 50 م 04:17:59 20/11/2018
7 microbiome P13 PQ-post heat @37 degree 14.9 0.297 0.2 1.49 1.79 DNA 50 م 04:18:59 20/11/2018
8 microbiome P13 PQ-post heat @37 degree 12.6 0.253 0.171 1.48 2.35 DNA 50 م 04:19:29 20/11/2018
9 microbiome P14 PQ-post heat @37 degree 68.1 1.362 0.773 1.76 1.92 DNA 50 م 04:20:14 20/11/2018
10 microbiome P15 PQ-post heat @37 degree 21.8 0.435 0.297 1.46 1.72 DNA 50 م 04:20:54 20/11/2018
11 microbiome P15 PQ-post heat @37 degree 19.6 0.392 0.255 1.54 1.86 DNA 50 م 04:21:34 20/11/2018
12 microbiome P16 PQ-post heat @37 degree 40 0.801 0.461 1.74 2.03 DNA 50 م 04:22:17 20/11/2018
13 microbiome P17 PQ-post heat @37 degree 36 0.72 -0.007 -108.99 1.83 DNA 50 م 04:23:07 20/11/2018
14 microbiome P17 PQ-post heat @37 degree 17 0.34 0.204 1.67 4.02 DNA 50 م 04:23:49 20/11/2018
15 microbiome P18 PQ-post heat @37 degree 30.9 0.618 0.357 1.73 1.49 DNA 50 م 04:24:35 20/11/2018
16 microbiome P19 PQ-post heat @37 degree 77 1.539 0.849 1.81 1.76 DNA 50 م 04:25:32 20/11/2018
17 microbiome P20 PQ-post heat @37 degree 70.7 1.413 0.783 1.8 1.9 DNA 50 م 04:26:47 20/11/2018
18 microbiome P21 PQ-post heat @37 degree 138.9 2.779 1.611 1.72 1 DNA 50 م 04:27:37 20/11/2018
19 microbiome P21 PQ-post heat @37 degree 29.8 0.595 0.342 1.74 2.69 DNA 50 م 04:28:08 20/11/2018
20 microbiome P22 PQ-post heat @37 degree 7.1 0.143 0.083 1.73 16.53 DNA 50 م 04:29:16 20/11/2018
21 microbiome P22 PQ-post heat @37 degree 8 0.159 0.092 1.74 6.86 DNA 50 م 04:29:56 20/11/2018
22 microbiome P23 PQ-post heat @37 degree 9.5 0.191 0.1 1.91 -21.29 DNA 50 م 04:30:54 20/11/2018
23 microbiome P23 PQ-post heat @37 degree 116.5 2.33 1.198 1.95 0.6 DNA 50 م 04:31:28 20/11/2018
24 microbiome P23 PQ-post heat @37 degree 50.5 1.011 0.304 3.32 0.9 DNA 50 م 04:31:56 20/11/2018
25 microbiome P23 PQ-post heat @37 degree 9.1 0.182 0.096 1.9 -4.4 DNA 50 م 04:32:33 20/11/2018
26 microbiome P24 PQ-post heat @37 degree 41.5 0.831 0.463 1.79 2.57 DNA 50 م 04:33:23 20/11/2018
27 microbiome P25 PQ-post heat @37 degree 51.5 1.029 0.572 1.8 1.8 DNA 50 م 04:34:21 20/11/2018
28 microbiome P26 PQ-post heat @37 degree 54.3 1.086 0.635 1.71 1.6 DNA 50 م 04:35:12 20/11/2018
29 microbiome P27 PQ-post heat @37 degree 35.7 0.715 0.434 1.65 1.07 DNA 50 م 04:36:02 20/11/2018
30 microbiome P27 PQ-post heat @37 degree 8 0.159 0.106 1.51 2.01 DNA 50 م 04:36:42 20/11/2018
31 microbiome P27 PQ-post heat @37 degree 9.3 0.186 0.112 1.67 2.13 DNA 50 م 04:37:19 20/11/2018
32 microbiome P28 PQ-post heat @37 degree 38.3 0.765 0.424 1.81 2.1 DNA 50 م 04:38:41 20/11/2018
33 microbiome P29 PQ-post heat @37 degree 113.7 2.274 1.222 1.86 2.09 DNA 50 م 04:39:30 20/11/2018
34 microbiome P29 PQ-post heat @37 degree 55.4 1.108 0.603 1.84 2.47 DNA 50 م 04:40:13 20/11/2018
35 microbiome P30 PQ-post heat @37 degree 36.1 0.721 0.401 1.8 2.91 DNA 50 م 04:41:11 20/11/2018
36 microbiome P32 PQ-post heat @37 degree 88.1 1.762 0.949 1.86 2.37 DNA 50 م 04:42:26 20/11/2018
37 microbiome P33 PQ-post heat @37 degree 22.9 0.457 0.261 1.75 3 DNA 50 م 04:43:01 20/11/2018
38 microbiome P33 PQ-post heat @37 degree 69.2 1.385 0.267 5.18 1.42 DNA 50 م 04:43:27 20/11/2018
39 microbiome P33 PQ-post heat @37 degree 22.4 0.448 0.253 1.78 3.44 DNA 50 م 04:44:30 20/11/2018
40 microbiome P34 PQ-post heat @37 degree 66.1 1.322 0.458 2.89 0.45 DNA 50 م 04:45:16 20/11/2018
41 microbiome P34 PQ-post heat @37 degree -0.4 -0.008 0.017 -0.45 0.17 DNA 50 م 04:45:45 20/11/2018
42 microbiome P34 PQ-post heat @37 degree -0.3 -0.006 0 -25.15 0.07 DNA 50 م 04:46:36 20/11/2018
43 microbiome P27 PQ-post heat @37 degree 8.7 0.174 0.096 1.81 1.8 DNA 50 م 04:47:15 20/11/2018
44 microbiome P34 PQ-post heat @37 degree -0.7 -0.014 -0.015 0.95 0.16 DNA 50 م 04:48:25 20/11/2018
45 microbiome P34 PQ-post heat @37 degree -0.5 -0.009 -0.003 2.98 0.1 DNA 50 م 04:48:57 20/11/2018
46 microbiome P34 PQ-post heat @37 degree -0.5 -0.011 -0.017 0.63 0.1 DNA 50 م 04:49:52 20/11/2018
47 microbiome P34 PQ-post heat @37 degree 66.3 1.326 0.492 2.69 0.44 DNA 50 م 04:53:21 20/11/2018
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APPENDIX IX- Quantification of samples post amplification and defragmentation. 
Nanodrop quantification post-amplification and defragmentation 
Quantification of samples post amplification and defragmentation and before the denaturation and 




Nanodrop readings for the purpose of the quantification of samples post-amplification and 




# Sample ID Nucleic Acid Conc. ng/µl A260 A280 260/280 260/230 Sample Type Factor Date and Time
1 post amp & defrag blank -0.4 -0.008 -0.017 0.48 0.51 DNA 50 ص 11:39:08 27/11/2018
2 post amp & defrag 1 125.5 2.51 1.341 1.87 1.72 DNA 50 ص 11:40:03 27/11/2018
3 post amp & defrag 2 101.3 2.026 1.09 1.86 1.67 DNA 50 ص 11:40:42 27/11/2018
4 post amp & defrag 3 108.5 2.17 1.176 1.85 1.69 DNA 50 ص 11:41:08 27/11/2018
5 post amp & defrag 4 106.4 2.128 1.142 1.86 1.7 DNA 50 ص 11:41:35 27/11/2018
6 post amp & defrag 5 106.8 2.137 1.145 1.87 1.72 DNA 50 ص 11:42:02 27/11/2018
7 post amp & defrag 6 106.1 2.121 1.135 1.87 1.71 DNA 50 ص 11:42:32 27/11/2018
8 post amp & defrag 7 108.7 2.173 1.174 1.85 1.71 DNA 50 ص 11:43:02 27/11/2018
9 post amp & defrag 8 105.5 2.11 1.127 1.87 1.69 DNA 50 ص 11:43:30 27/11/2018
10 post amp & defrag 9 108 2.16 1.176 1.84 1.71 DNA 50 ص 11:44:10 27/11/2018
11 post amp & defrag 10 107.4 2.148 1.17 1.84 1.7 DNA 50 ص 11:44:35 27/11/2018
12 post amp & defrag 11 106.8 2.135 1.152 1.85 1.7 DNA 50 ص 11:44:57 27/11/2018
13 post amp & defrag 12 105.9 2.118 1.145 1.85 1.71 DNA 50 ص 11:45:17 27/11/2018
14 post amp & defrag 13 106.4 2.127 1.151 1.85 1.68 DNA 50 ص 11:45:38 27/11/2018
15 post amp & defrag 14 108 2.159 1.169 1.85 1.7 DNA 50 ص 11:46:04 27/11/2018
16 post amp & defrag 15 109.6 2.191 1.187 1.85 1.71 DNA 50 ص 11:46:25 27/11/2018
17 post amp & defrag 16 117.4 2.347 1.269 1.85 1.72 DNA 50 ص 11:46:46 27/11/2018
18 post amp & defrag 17 105.1 2.103 1.141 1.84 1.67 DNA 50 ص 11:47:21 27/11/2018
19 post amp & defrag 18 106.5 2.131 1.155 1.85 1.7 DNA 50 ص 11:47:38 27/11/2018
20 post amp & defrag 19 105.6 2.112 1.153 1.83 1.69 DNA 50 ص 11:47:59 27/11/2018
21 post amp & defrag 20 113.6 2.273 1.222 1.86 1.7 DNA 50 ص 11:48:21 27/11/2018
22 post amp & defrag 21 109.7 2.194 1.185 1.85 1.69 DNA 50 ص 11:48:40 27/11/2018
23 post amp & defrag 22 108.7 2.175 1.178 1.85 1.68 DNA 50 ص 11:49:00 27/11/2018
24 post amp & defrag 23 9.7 0.194 0.131 1.49 0.47 DNA 50 ص 11:49:22 27/11/2018
25 post amp & defrag 24 101.7 2.034 1.098 1.85 1.66 DNA 50 ص 11:49:58 27/11/2018
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APPENDIX X- Diversity metrics 
 
Name Units Description 
richness OTUs 
Number of OTUs with at least one read for the 
sample. 
mirror OTUs See mirror estimator. 
FE OTUs See singleton-free estimator. 
chao1 OTUs 
Chao-1 estimator, calculated as N + S2 / (2 D) 
where N is the number of OTUs, S is the number 
of singleton OTUs and D is the number of doublet 
OTUs, i.e. OTUs with abundance 2. 
shannon_2 bits Shannon index (logs to base 2). 
shannon_e nats Shannon index (logs to base e). 
shannon_10 dits Shannon index (logs to base 10). 
jost OTUs 
Jost index of order q where q is specified by the -
jostq command-line option, default 1.5. 
jost1 OTUs 
Jost index of order 1, the effective number of 
species given by the Shannon index. 
  
Evenness metrics 
Name Units Description 
simpson Probability Simpson index, calculated as the sum over 
OTUs of f2 where f is the frequency of the 
OTU. It is the probability that two randomly 
selected reads will belong to the same OTU. A 
value close to 1 indicates that a single large 
OTU dominates the sample, small values 






Probability Probability that two randomly selected reads 
will belong to different OTUs. Calculated as 1 - 
Simpson. 
equitability ? Also called Peilou's evenness. Entropy 
(Shannon index) divided by the logarithm of 
the number of OTUs. Value of 1 indicates 
perfectly even (equal abundances), small 
values indicate a highly skewed abundance 
distribution. 
robbins Frequency Robbins index, calculated as S / (N + 1) where 
S is the number of singleton OTUs and N is the 
total number of OTUs. 
berger_parker Frequency Berger-Parker index. Frequency of the most 
abundant OTU. A value close to 1 indicates 
that a single large OTU dominates the sample, 
small values indicate that the reads are 
distributed over many OTUs. 
 Other 
Name Units Description 
reads Reads Total number of reads for the sample. 
 













APPENDIX XI- Gant Chart 
GHANT CHART showing the timelines (year 1) 
 
 
